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ABSTRACT
This investigat.ion examined the effect,s of four weeks of
therapy with either aerosol flunisolide or placebo inhaler on
exercise-induced bronchospasm (EIB). Measures of exercise
performance, exercise-related pulmonary funct,ion, sympE,omology
and toEal eosinophil count, were used t,o monitor t,he impact of
treatment on EIB. SubjecEs with moderately severe ast,hma (as
deEermined by sympEomat,ic criteria) who had not, used steroid
medications in the two mont,hs prior t,o Eheir enrollment, in the
sEudy and who committed t.o maint,aining a sEable patEern of
physical act,ivity during the study were invited. to
parE,icipat,e. Six subjecEs, aged 18 Eo 45 (four males and two
females) compleEed the sEudy. SubjecEs were tesEed Ehree to
four times, depending on Eheir usual pat,E,ern of ast,hma
treatment,. At each tesE, session, subjecE,s completed a maximal
graded e:iercise EesE (GxT) , pulmonary funcEion Eest,s (PFT) and
a symptomologf rating quest,ionnaire. During the last, Ehree
EesEs (which compared usual treatmenE, regimen, flunisolide
E,reatment and placebo t,reatmenE) , a E,otal blood eosinophil
counE was also collect,ed. Two-way (3 x 3) analyses of
variance (AIIOVA) for preexercise and 5 and 15 minuE,e
postexercise PFT, t,wo-way (3 x 2) AI.IOVA for maximum
post,exercise changes in PFT (dPFT) , and one-way AIiIOVA for
exercise perf ormance-, s)mpE,omology raE,ings and. t,otal
eosinophil count, faited io reveal stat,istically significant,
changes between Ehe Ehree E,reatment phases of t,he sEudy. The
Iimited lengt,h of the treatment phases, interference caused by
preexercise treaEment, wiEh bronchodilat,ors, or a genuine lack
of efficacy of aerosol flunisolide therapy are among t,he
possible explanat,ions for E,hese apparent, findings of sEeroid
ineffecEiveness in improving EIB, PFT or exercise performance
for asEhmatics with moderat,ely severe disease.
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IMTRODUCTION
Ast,hma is a cortrnon inflanrnatory lung disease
characEerized by episodes of reversible air:way
obst,rrrcEion. Approximately 70-90t of people who have
asthma have s).mpEoms triggered by st,renuous physical
act,iviE,y; referred Eo as exercise-induced bronchospasm
(EIB). This condition may someEimes occur independently
of allergic or irnrnunologically regrulaE,ed asthma.
(McFadden, Jr. a Gilbert,, L994; Mahler, 1993; Virant,
L992) .
An improved underst,anding of the role of t,he
inflammaEory process which causes and perl>eEuat,es asEhma
has led to sweeping changes in t,herapeutic management, of
E,he disease (McFadden, Jr. & GilberE, L992) . Previously,
reversal of bronchospasm was t,he primary goal of therapy.
The current, focus lies on using a combination of aerosol
corticosteroids Eo heal airvray inflanunaE,ion and quiet t,he
underlying basis of t,he disorder while concurrent,ly using
B-adrenergic agonist, medications t,o relieve airway
obstnrct,ion. The demonst,rat,ed efficacy and long term
safety of modern pharmaceuEicals have made Ehese goals
at,t,ainab1e. Unfortunately, many people with ast,hma and
EIB are inadequately t,reaE,ed. Reasons include an
incompleEe underst,anding of t,he laEesE guidelines for
management, (which have appeared in primary care medical
Iiterature only in the 1asE, t,wo t.o t,hree years) , paEient,
and healt,h care provider concerns regarding the pot,ential
risks of corticost,eroid therapy (Barnes, 1989), and
underraE,ing of E,he severit,y of disease by both patienE
and healt,h care provider (Kikuchi eE a1., L994) .
Unst,ab1e asEhma can predispose pat,ient,s to EIB and
performance-limiting dyspnea (S1y, 1986). There has been
IiE,t,Ie sEudy regarding management, of underlying ast,hma as
a E,reaEment for EIB and whet,her Ehis st,raE,egy can improve
exercise tolerance. The goal of this invesCigation was
to examine whet,her strict, conE,rol of moderaEe asthma, in
accordance wit,h Ehe reconrnendaE,ions of t,he 199L Nat,iona1
InstiEut,es of Healt,h ExperE, Commit.t,ee on AsEhma (National
AsE,hma Education Program Expert, Panel ReporE, , 1991-) , can
influence EIB and exercise performance. These guidelines
specifically reconunend maint,enance t,herapy with aerosol
cort,icosteroids for moderaE,e asthma. Therefore, E,he
purpose of t,his st.udy was Lo determine if four weeks of
cort,j-costeroid t,reatment in moderately severe ast,hma
paE,ienE,s could improve exercise performance and related
pulmonary funcEion.
A review of lit,erature on Ehe pathophysiololly,
diagnosis and t,reatmenE of ast.hma is included in Appendix
A. Exercise-induced asthma, pulmonary function testing
and pharmaceut,ical agent,s are also reviewed.
METHODS
Subject,s and Subject Selection
A total of six subjects part.icipat,ed in this study.
Ages ranged f rom 18 t,o 45, wiEh a mean of 29 .3 years.
Four subject,s were male and two were female. Telephone
screening was used Eo rate severity of asE,hma based on
the pat,E,ern and frequency of exacerbations and medication
use as weII as t,he currenE and project,ed st,abilit,y of
exercise pattern. Only those with moderaE,e asthma
(defined as >L-2 exacerbaEions per week and/or >2
episodes of noct,urnal symptoms per monE,h) who also had
st,able exercise patterns were invited to parEicipat,e. A
stable exercise pattern was defined as having the same
weekly regimen (number of days per week, leve1 of
intensit,y, etc. ) for two months before Ehe sEudy began
and promise that. Ehe regimen would not, change during the
study. Subjects who had used any form of corEicosteroid
in t.he two mont,hs prior to the sEudy were excluded. The
risks and benefits of participation were t.horoughly
reviewed, and informed consenE (Appendix B) was obt,ained
during the first, meet,ing with each subjecE. The
experimenE, prot,ocol was reviewed and approved by Ehe
Human Subjects Research Cormnittee at lt,haca College. The
primary healEh care provider for each subjecE was
notified and provided with relevant, sEudy information and
currenE ast,hma t,herapy reference materials (Appendix C)
Each subject visiEed t,he Exercise Physiology Laboratory
one or two times to assess t,he efficacy of t,heir usual
regimen of medicat,ions in prevent,ing exercise-induced
bronchospasm and again aft,er each of t.he two t,reatment
phases of t,he study. The details of t,hese visit,s are
described below
Prot,ocol
This study was conduct,ed over four sessions and a
double bIind, placebo conErolled, crossover model was
used. The first. meet.ing, designed Eo document t,he degree
of EIB E,riggered by sE,renuous act,ivit,y when Ehe patienE,
was in an unmedicaEed sEate involved complet.ion of a
questionnaire (Appendix D) . This suryey inquired about
recent f requency and severit,y of asLhma and EIB sympt,oms,
medication use, exercise paEtern, and any currenE
illnesses. IE, was also conf irmed for t,his and all
subsequent tesls E,hat no medicaE,ions or exercise preceded
t.he session for aE leasE four hours. A limited physical
examinat,ion focusing on Ehe ears, nose, t,hroaE, skin, and
cardiovascular and pulmonary syst,ems was conduct,ed to
rrrle out, Severe, unslable asthma or cgncgmitant medical
conditions. During E,his f irst, meet,ing a review of t.est,
procedures and eqqipment, familiarized each subject with
the proEocol of t,he study. Baseline height and weighE
were measured and baseline unmedicated, preexercise
spirometry consisEing of forced vital capacity (FvC),
forced expiraEory volume at one second (FEV1) and maximal
midexpiraEory flow rate (MMEFR) were measured with a CDx
Spiro 110 PIus spiromeEer (CpX Corp, Providence, RI).
Open circuiE, spiromeE,ry allows these values Eo be
calculaEed from a forced maximal expiraE,ion based on
measuremenE of the pressure and duraEion of air flow past
a t,ransducer in t,he spirometer. Subj ecEs were t,aught t,he
technique of forced exhalat,ion and the maneuver was
repeat.ed unt,iI at, Ieast, 2 mat.ching tesE.s were recorded.
.A,I1 maneuvers were analysed and t,he highest value
attained for each specific PFT was reporE,ed. Peak
expirat,ory flow rate (PEFR) was measured with an Ast,ech
Peak Flow Meter, (Center Laboratorj-es, PorE Washingt.on,
M) . Baseline pulmonary function tests (PFT) were
conducE,ed imrnediately before t,he graded exercise t.est,
(Gxr) 
.
A maximal GXT was conduct,ed according to t,he Bruce
prot,ocol on a SensorMedics 1900 Ereadmill (Marquette
Electronics, Milwaukee WI) while t,he heart, raEe and
rhyt,hm were continuously monit,ored via a SensorMedics
Max-1, 12-lead elect,rocardiograph (Marquet,Ee E1ect,ronics,
Milwaukee, wI). The Brrrce prot,ocol, with three minuE,e
sEages, was chosen t,o det,ermine maximal oxygen
consumpEion (VO, max) as well as trigger symptoms.
Numerous sEudies (KyIe, Walker, Hanshaw, Leaman, &
Frobase, L992; McKenzie, McLuckie, & Stirling, L994; Rohr
et, al. , L987 ) have demonst,raEed t,hat exercise at, a level
of 8O-9Ot predicted maximal hearE, rat,e (HR max) for six
t,o eighE minut,es will trigger EIB. Therefore, iE, was
expect,ed that, Ehe 1ast, two sE,ages of the Bruce proEocol,
with heart rat,es greaEer Ehan 80? maximal, would
poEenEially evoke EIB. RaE,ing of perceived exerE,ion
(RPE) was assessed aE the end of each GXT sEage. Oxygen
consumpt,ion was measured using indirect calorimetry via
analysis of expired air with a SensorMedics 29OO
Metabolic Measurement Cart (SensorMedics, Yorba Linda,
CA) . ExhausE,ion and/or performance-limiting dyspnea were
considered endpoint,s for the Eest. A Ewo minute cool
down period aE 2 MPH and 0t grade was allowed.
At, 5 and 15 minut,es after exercise PFT were measured
again. These measures were made aE, E,hese t,imes because
mosE subject.s undergoing challenge Eesting have maximal
changes in PFT within five minut,es of compleEion of
exercise (Freed, Bromberger-Barnea, & Menkes, 1985).
Aft,er all dat,a co1lecE,ion, t.he subjecEs were allowed E,o
use bronchodilaLing medicat,ions for sympEomatsic relief as
necessary and a ranking of sympt,oms as well as Ehe number
and t.iming of doses were recorded. When the subjecErs
condition had normalized, subseguent sessions were
scheduled and t,he subject \das released.
A second Eest, was conduct,ed approximaEely one we6k
Iat.er to assess Lhe ef fect,iveness of t,he paeient.'s usual
regimen of EfB prophylaxis. The subjecE was asked Eo
foIlow t,heir E,ypical paEt,ern of medication dosing before
exercise. For subjecEs who normally did not. use
bronchodilacors before exercise, Eest, sessions one and
two were combined into a single EesE since it would
represenE both an unmedicated stat,e as well as E,heir
usual regimen. An int,erval hisEory form which assessed
syrnptomology, medication use, healEh sE,aE,us and exercise
patEerns of t,he Ewo weeks preceding E,he t,est was
reviewed. A second GXT with preexercise and postexercise
PFT (now assessed in a medicated staE,e for those subjecEs
who normally use preexercise bronchodilators) was
conducEed in a fashion ident.ical to Ehe firsE, tesE. fn
an efforE t,o control for E,echnique-relat,ed variaE,ions in
aerosol drug delivery for t,he remainder of t,he sEudy,
ideal metered dose inhaler (t\DI) use was Eaught, during
the second laboraEory visit and a pat,ient educat,ion sheet,
was provided at this t,ime (Appendix E) . Venipunct,ure was
performed to obtain a blood specimen for analysis of
baseline t,otal eosinophil counE, a general marker of
immunologic activation in ast,hma (O'Hara, 1995; Barnes,
1989). The blood sample was collecE.ed wit,hin 24 hours of
the second tesE, and before starting t,he steroid or
placebo inhaler t,reatmenE phases of t,he experiment,.
Following a double blind format,, a MDI containing
either aerosol flunisolide (Aerobid, 250 mg/inhalat,ion;
Forest. Pharmaceut,icals, SE. Louis, MO) or placebo
(propellent, only) was randomly assigned and the pat.ient
was instnrcE,ed t,o use Ewo inhalations Lwice daily for Ehe
next four weeks. Each patient was also instmcted to
rinse out t,heir mouth after dosing to reduce Ehe risk of
side effects and to minimize the aftertaste of
flunisolide. Rinsing also helped prevenE, potenE,ial hints
as to wheE,hef a subject was in t.he Ereatment or placebo
group (Ka1iner, 1990; UEiger, 1993) . Interim t,elephone
interviews two weeks after the second and third test
sessions were conducE,ed Eo reinforce compliance with the
treatment regimen and E,o det,ermine if the pat,ienE was
experiencing any side effecE,s. This was done for
pat,ient,s in bot,h Ehe t.reaEmenE and placebo groups.
The t,hird E,est session was conducted four weeks
afE,er t,he second EesE and followed precisely t,he same
hisLory review and t,esE proEocol as the firsE t'wo
sessions. Repeat, venipuncture was performed Eo deEermine
any changes in t,oEal eosinophil count,. Subject,s were
t,hen assigned to the alEernate course of treaEmenE
・  …  ・ ‐ ― ― ‐ ¨ ― ― … … …  … … ― … … … …        … 一 一
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(aerosol placebo or flunisolide) for Ehe nexg. four week
period.
The fourEh and final t,esE session precisely repeated
t.he hist,o41 review, GxT, PFT, and blood testing
procedures of sessions two and three. A debriefing
session Eo review individual results was offered at a
future t,ime when all subjecEs had completed E,he sE,udy and
t,he two Ereatment,s had been revealed.
St,aE.istica1 Analysis
Directly measured PFT values (FvC, FEv1, PEFR,
MMEFR) were evaluaEed via two-way (g x 3) analysis of
variance (ANOVA) test,s. Three treaEmenE phases (usual
medicat,ion, flunisolide t,herapy and placebo) and t.hree
t,est, intenrals (preexercise, five minuE,es posE,exercise
and 15 minut.es postexercise) were considered. A 3 x 2
AIIOVA was used for analysis of t,he maximum percent change
PFT (dFvC, dFEV1, dPEFR and dMMEFR), comparing the three
treaEment, phases with calculated PFT measurements
(preexerciSe versus lOweSE posgexerCiSe values, recorded
at, eit,her 5 or 15 minuE.es postexercise). A 3 x2 AIitOvA
was also used to examine bronchospasm SympEom raEings
measured at. 5 and 15 minuEes posEexercise. Finally, a
one-way AI.IOVA was used Eo assess effecEs of Ehe Ehree
treaEmenE phases on exercise perfonnance dat,a (HR max,
VO, max, RPE max, GXT duraEion and Ve max) , tot'al
eosinophil counE and symptomology indicaE,ors. Data were
assessed aE the p < 0.05 level of significance.
Safety PrecauEions
During t,he entire sEudy several safety procedures were
followed Eo minimize risks t,o the pat,ienc. In addition Eo
t,he Human Subjects Research Conunittee review and approval,
a college staff physician with sports medicine specialEy
training reviewed all protocols and emergency procedures.
Tests were noE conducted if E.he pat.ienE's asEhma or
allergies were especially unst,able or if t,he pat,ient had
concurrent, illness. PaE,ienE,s were required to bring Lheir
own prescripEion B-agonisE bronchodilat,or IIDI t,o each Eest
session. A11 Eesting was done under the direcE. supervision
of a board-certified physician assist,ant, and nebulized
albuE,erol solut.ion, oxygen and airway management, equipmenE,
were available in the laboratory. Pat,ients were not,
allowed Eo leave tesE, sessions until afEer pulmonary
function normalized t,o wit.hin 30t of predicEed values.
Rout.ine medical and emergency care was available aE Ehe on-
campus sEudenE healt.h cent,er 24 hours per day, seven days
per week. Finally, bimont,hly Eelephone surveys were
collect,ed t.o check paEient st,atus during t,reatment, phases
of Ehe sEudy, and paEienE, educat,ion sheets which deEailed
danger signs of deterioraEing ast,hma (Appendix F) were
provided to each subject.
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RESULTS
Intersubject variability, or the expecE,ed
"uniquenessfi of E,he raw scores of each subject, based on
the somat,ic charact,erist,ics, gender and physical
condit,ion, was consisE.ent,Iy demonst,rated by ANOVA for
each indicator. However, from a pracE,ical and clinical
perspect,ive, the heterogeneit,y of t,he sample was
irrelevant, and impacted 1it,t,Ie on the treatment, regimen
and expect,at,ion of result,s. Refer to Appendix F for AIiIOVA
t,ables (Tables F-1-19) and descriptive sEat,istics (Tables
F-20-27). Refer to Appendix G for raw data Eables
(Tables G-1-6) .
Exercise Performance Dat,a
HR max, VO, max and RPE max during E,he GXT as well
as t.esE duration were measured as indicaLors of exercise
performance. No sEatistically significant changes were
found in any of t,hese measures beEween flunisolide and
placebo treatment, groups (Tab1es F-1-4). The stability
of Ehese numbers (Table F-20) suggest,s thaE, t,he maximum
level of exerE,ion was successfully achieved in each Eest,.
' Pulmonary Function TesEs
PFT included measurement, of Ve max during t,he GXT
(Table F-5). It was possible that minimal changes might
be expecE,ed wiEh sEeroid EreaEmenE, but, no st,atist,ically
significant changes relaEed to t,reaEment were observed.
■■
FVC, FEV1, PEFR, and MMEFR all remained unchanged in
reference t,o treatment. wit.h flunisolide or placebo
(Tables F-2L-24) . FurEher, t,here were no sE,at,istically
significant, changes in preexercise versus postexercise
measuremenEs of pulmonary volumes or flow rates (dFvc,
dFEV1, dPEFR, dMMEFR; Tables F-10-13, Figures 1-4) which
reflecE, airway reactivity. SubjecEive rating of sympt,oms
5 and 15 minut.es aft,er reaching their maximal exercise
tolerance showed no stat,istically significanE, change
despice an anticipaE.ed improvement, with steroid inhaler
treatmenE, (Tab1e F-20) .
Eosinophil Count
Total eosinophil counE, suggested as an indicaE,or of
immunological activat,ion (O'Hara, 1-995,' Barnes, 1989),
remained sEable and did not change Eo a sEat,istically
signif icanE degree in relaEion E,o EreatmenE,. Refer E,o
Table F-20 for mean scores relat,ed to t,he effects of
treatment wit,h usual medicaE,ion, flunisolide and placebo.
. 
Symptomologry Rat,ing
Measures of sympt,om act,iviEy were det,ermined by
bronchodilat,or medication use (number of days per week
and number of doses per week) and oEher factors. Ratings
of exercise and nonexercise-relaEed ast,hma, EIB frequency
and severigy, noct,urnal symptoms and an overall ranking
of asEhma severiEy were also examined. No staEisEically
■2
significanf. changes were noted in the subjectrs rating of
s)mpE,omologlf with relat,ion to t.reatment,. Mean scores and
st,andard deviations for each E,reatment, and Eest can be
found on Table F-20.
Selected MeasuremenE,s By St,age
VO, max, HR max and Ve max achieved during t,he GXT
were examined by E,est stage. These measures showed no
st,at,ist,ica11y significanE, main effect, changes due to
flunisolide E,herapy (refer t.o Tables F-25-27 for mean
scores) . Stat.istically significanL, buE, physiologically
normal changes, were noted in relat,ion E,o t.he stage of
Ehe GXT. This was an expecE,ed response reflecting
increasing workloads of Ehe progressively more difficult,
GXT stages (Tables F-25-27).
Maximum postexercise changes in PFT (dFVC, dFEV1,
dPEFR and dMMEFR) are present.ed graphically in Figures 1-
4. CalculaLed by comparison of a specific preexercise
PFT wiE,h E,he lowest, recorded postexercise measuremenE,
(whet,her this occurred aE. 5 or i-5 minuE,es post.exercise) ,
these values are st.andard measures of ainuay reacE,ivity
(Ky1e, Walker, Hanshaw, Leaman, & Frobase, L992; ViranE,,
L9921 . None of E,hese calculaE,ed values appear t,o be
altered by the t.reaEmenE,s used in Ehis study. fnspection
of t,he graphs (Figures 1-4) fails t,o reveal a t,rend when
comparing t,he posE,exercise pulmonary funct,ion changes of
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subjects in
flunisolide
relation
therapy,
EO
or
usual EreatmenE, regimen,
t,reaEment, with placebo.
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DISCUSSION
The goal of this sE,udy was E,o deEermine if
aggressive EreaEmenE of moderat,ely severe asEhma could
improve exercise performance. This was assessed by
indicaLors including GxT duraE,ion, RPE max, HR max, VO,
max, preexercise versus post,exercise PFT (FVC, FEV1,
PEFR, MMEFR, dFVC, dFEV1, dPEFR, and dMMEFR), and
sympt,omologf raEing by Ehe subject. Total eosinophil
counE was also moniE,ored as a marker of inrnunological
activaE,ion.
Exercise Performance Assessment
One of t,he fundamental issues E.his st,udy was Eo
address whether improved cont,rol of asthma and
sEabilizaEion of airway react,ivity could enhance physical
performance. If such an improvement could be
demonsE,raEed, people with asthma would have an effective
technique to minimize the poE,enEial handicap imposed by
EIB.
Indicat,ors of exercise performance did noE change
significantly with respect, E,o Ereatment wieh sEeroid or
placebo inhalers. The overall st.abiliEy of t,hese
measures may reflecE, subject,s who had st,able paEEerns of
physical activit,y and conditioning, and demonstrat,ed only
moderaE,e ast,hma. The uniformity of results also suggesEs
t,haE subjects were consisEent,ly reaching both perceived
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and measured maximal levels of exercise int,ensity.
Additionally, flunisolide treatment may not have produced
drastic changes because these performance measures are
fairly broad indicaEors and may noE. be sensit,ive enough
E,o ref tect subt,le improvemenEs. IE should also be
remembered t,haE subjects conE,inued Eheir usual asthma
treaEment t,hroughouL the sLudy which for t,hree of t,he six
subject,s included preexercise bronchodilaE,ors to blunt
the effect of EIB. Prophylact,ic use of bronchodilators
have long been considered a standard Ereatment of EIB
(McFadden & Gilbert, 1994; Mahler, L993) yet additional
improvemenE,s in exercise performance might Eheoretically
be achievable if steroid Eherapy were able E,o furE,her
st,abilize airway funct,ion against, activity-relaEed
sympEoms. This, however, was not, demonst,rat,ed in t,he
present sEudy and bronchodilator use may have masked a
beneficial effect of flunisolide on exercise performance.
Pulmonary FuncE,ion Test,s
The second major quest,ion t,his study addressed was
wheEher flunisolide therapy could improve exercise-
relaEed pulmonary funct.ion. fE was anEicipaE,ed t,hat the
most clinically imporEanE changes related Eo flunisolide
Ereatment, would be improvements (decreases) in air:vray
h14>erresponsiveness as t.he inhaled sE,eroid moderated E,he
inflanunatoqf changes and bronchospasm associaE,ed with
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underE,reat,ed, moderaE,ely severe asthma (Katz, L986;
Mah1er, 1993; Virant, 1992) .
However, observation of Ve max, WC, FEV1, PEFR,
MMEFR and s)mpt,om rat.ings (each measured preexercise as
well as 5 and 15 minut,es posE,exercise) did not support
this expected finding. Addit,ionally, no st,aE,isEically
significant, changes were noted in dFVC, dFEV1, dPEFR or
dMMEFR. Of all PFT examined, maximum percent, change
values should have been mosE Iike1y t,o demonstrate a
treatmenE-related response, and the lack of effecE due to
treaEmenE, was surprising.
Several facE,ors may account, for this apparenE, lack
of effect associated with aerosol st,eroid treatment. One
explanaEion may be Ehat. a longer period of t,reatment, is
required to demonst.rate a therapeutic effect. Clinical
improvement is usually expect,ed t.o begin within
approximaEely two weeks after sE,arE,ing Eherapy, and a
four week Ereatment. period was t,hought Eo be adequat,e for
the purposes of Ehis sE,udy. However, from a clinical,
patient management perspect.ive, a six to eight week
treatment, phase would probably be pursued Eo confirm lack
of effecE,iveness if no channges were noEed in an iniE.ial
four week E,herapeut,ic trial of aerosol sE,eroids (KyIe,
Walker, Hanshaw, Leaman, & Frobase, L992; National AsE,hma
EducaEion Program Expert, Panel Report, L99L) .
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Anot,her fact.or which could account, for t,hese result.s
may be Ehe small number of subjecEs in t,his sEudy and t,he
resulting lack of staEistical power. One trend not,ed in
Ehe PFT daEa was t.haE subject,s who did noE normally use
bronchodilaE,or treaEment, before exercise showed the mosE
dist.inct st,abilization in dMMEFR, t,he PFT which bese
reflects small to mid-sized airway function. If this
invest.igation were extended Eo a larger number of
subjects, the findings may confirm these Erends or
perhaps more clearly delineat.e subgroups who may benefit,
from strict conErol moderate asthma.
A t,hird explanat,ion may be that, aerosol steroid
treaEment genuinely does not, offer performance enhancing
benefits great,er t,han a regimen of preexercise
bronchodilators for E,hose people who use t,hem.
BronchodilaE,ors have the pot,enE,ial to t,emporarily
minimize air-way h14>erresponsiveness even in the setting
of ongoing airway inflarmnation and subjects who use t,hem
could mask subEle improvement,s in pulmonary funcEion
associat,ed with aerosol sEeroid Eherapy (Kerstjens et
dI., L9921 .
Some anticipated preexercise versus post,exercise
declines in PFT did occur but, these exhibited no
difference due Eo Ereatment. Instead, Ehese changes
ref1ecE, the expecEed effect of prolonged, st,renuous
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acEivit,y provoking some degree of bronchospasm in
asthmat.ic subjects with result,ing declines in
postexercise pulmonary function.
Indicators of Sympt.omology
This invest,igaEion also examined t,he impact of
flunisolide therapy on the part,icipanEs subjecEive
ratings of bronchodilaE,or use (number of days per week
EreaEmenE, was necessary and number of doses per week),
sympt.oms relaE,ed or unrelaEed t,o exercise, nocturnal
symptoms, EIB freguency and severity and a ranking of E,he
overall severity of asthma syrnptoms in the two week
period preceding each GXT. These indicators were
considered import,ant because sympt,oms, in addiEion to
PFT, are considered main crit,eria for diagnosis and
moniEoring of ast.hma patient,s. Subjective rat.ings of
symptoms are often used t,o deEermine whet.her a patient
needs to adjust, dosage or seek medical consult,ation.
Finally, acuE,e sympt.oms cause very real discomfort. for
the person enduring them. Improved symptomatic conErol
can represent, a decrease in physical and psychological
distress even in E,he absence of improved exercise
performance (National Ast,hma Education Program E>cpert,
Panel Report, L992) .
fn Ehis sE,udy, none of the s)rmpt,omological
indicat,ors showed any stat,ist,ically sigrnificant, changes
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between baseline, steroid, and placebo t,reatment.. At
leasE, some minor change was ant,icipaE,ed in t,he frequency
and severity of asE,hma and EIB during Ehe corE,icosteroid
therapy (Barnes, 1989; Kaliner, 1990; Li & Reid, L992).
That, no change occurred could be linked Lo some import,anE,
facEors.
Several other Eriggers of bronchospasm and at,opy
(allergens, irrit.ants, cold air exposure and respiratory
infection) could not be easily cont,rolled. Any of t,hese
triggers of airway inflarmnaE,ion could precipitat,e or
perpetuat,e hytrlerresponsiveness (O'Hara, 1995; Rollason,
1995) and offset synrptomaEic improvement related to
therapy. Accordingly, a dominaEing fact,or, such as the
prevailing cold weaEher during t,his study may have masked
any immediate benefiEs of the treatment on indicators of
symptomologf.
AnoEher factor which needs to be considered is E,haL
subjecE percept.ion of sympE,oms can correlat,e poorly with
more object,ive assessment of st,aEus (Rollason, L995;
Kikuchi et aI., t994) . Measurable changes in PFT may noE
be apparenE to the subjecE, ofEen making paE,ient rat.ings
of s)rmpt,oms inaccurat,e. In an at,t,empE, to control f or
t,his, sympt.omology indicat,ors included boE,h trsofEu
variables based on t.he paEients raE,ing of disease
activity and trhard" variables which examined the amounE
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of medication Ehe patient, required in the two weeks
preceding the t,esE. BronchodilaE,or medication use was
also no different, bet,ween the flunisolide and placebo
phases of treatment.
The limited number of subject,s may have played a
role in t,he lack of significant sympt,omologlf findings as
was reviewed in the discussion of PFT. A larger number
of subjecEs in this study may have revealed t'rends or
findings of staE,istical significance. Final1y, a tnre
lack of effectiveness of flunisolide t,herapy in
prevent,ing EfB musE also be considered in a t,horough
review of explanaE,ions for these findings.
Tot,a1 Eosinophil Count
The Eot,al eosinophil count was monit,ored in an
at.Eempt Eo assess inununological act,ivaEion (O'Hara, 1995;
Barnes, 1995). No statisEically significanE effecEs
associated with steroid or placebo treaEment were noted
alt,hough a decrease in eosinophils was an ant,icipated
finding. Alt,hough Ehe sensit,ivity and specificity of
this part,icular marker is not, widely documented, iE, is
the only readily measurable humoral marker associaEed
wiE,h asE,hma. The inclusion of Ehis indicat,or represent,ed
a novel approach t,o sEudying E,he degree of at,opy
associated with various asE,hma t,reatments. General
immunological activaEion from t,riggers beyond the cont,rol
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of t,he study (al1ergens, irritants, cold air exposure and
respirat,ory infecEion) and lengt,h of treatmenE may also
have impacted on total eosinophil counE, and the
possibility of a genuine lack of effect,iveness of sE.eroid
t,reatment on this indicaEor musE also be considered.
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CONCLUSIONS
Result,s of this investigat,ion show no st,atisEically
significant changes t,hat would suggesg aggressive therapy
for moderat,e asEhma provides any advantage over a
patientrs usual regimen of EIB managemenE. There are
cerE,ainly benefits t,o be gained from st,rict control of
moderat,e asEhma including a decreased risk of morE,alit,y
and morbidity as well as an improved qua1iE,y of tife
(NaE.ional AsE,hma Education Program Expert Panel Report,,
L99L; Barnes, 1989; McFadden & Gilbert, L992) . However,
the results of E,his invest,igation suggest, thaE,
enhancement of exercise performance should not be viewed
as a possible benef iE at t,his time. This understanding
of the probable lack of performance enhancement, provides
asthmatics a clearer sense of therapeutic expectations
from strict control of moderate asthma.
At, t,his point, in Eime, iE seems, t.hat, cont,rary Lo
the original h14>ot,hesis of this study, aggressive
management of moderately severe asthma with four weeks of
aerosol steroid t,herapy has no impact, on exercise
performance, exercise-r.i.t.d pulmonary funct,ion, asEhma
and EIB symptomologlf , or Eot,al eosinophil counEs. This
should not be const,rued as a reject,ion of strict
management of asEhma, however, which offers numerous,
nonexercise-related benefiEs to the paEient,. Hopefully,
23
additiona■ studies wi■l shed further ■ight on idёa■ EIB
therapy′ and aeroso■ corticostero■d medications w■■■ be
prescribed and used for appropriate and rea■istic
treatment goa■s.
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Figure 1. Mean maximum postexercise
change in EVC (dEVC) . Calculated as
Iowest postexercise EVC,/preexercise
EVC x 1008 11 : 6.
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in FEV1 (dFEVL). Calculated as
postexercise EEV1/Preexercise
FEV1 x L00B 11 : 6.
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3. Mean maximum postexercise
in PEER (dPEFR). Calculated as
postexercise PEFR/preexercise
PEFRx100% n:6.
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Figure 4. Mean maximum postexercise
change in MMEFR (dMMEFR). Calculated as
lowest postexercise I'["IEFR/preexercise
MMEFR x L00E 11 : 6.
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APPENDIX A
LITERATURE REVTEW
InE,roducEion
Ast,hma is a pulmonary disease characterized by
episodes of variable airflow obsErucEion which can
resolve spont,aneously or require medical t,reaEment.
Bronchospasm, airway inflarunation and abnormal mucus
production all contribute t,o narrowing of respiraEory
passageways and cause the classic asthma s)rmpt,oms of
shortness of breath (dyspnea), wheezing, and coughing.
The costs, incidence, and severity of this disease are
increasing despit,e the availability of effective drug
therapy (Barnes, 1989) .
An est,imat,ed 9-15 million people in the United
States have asEhma and the cosE, for care of t,he disease
was 56.2 billion in 1990; t,he cosE of medicaEion alone
was nearly $713 million (Weiss, Gergen, & Hodgson, L992).
The occurrence of asE,hma has increased 35? beEween L982
and 199L (Rollason, 1995), and despite a decrease in
asEhma mort,ality from 1958 through Ehe L970's, Ehe rat,e
of ast,hma-relat,ed deaEh has sEeadily increased since Ehe
early 1980's; beEween 1980 and 1989 the age adjusEed
deaE,h raE,e rose 45t (from 1.3 Eo 1.9 per L00,000)
(Rollason, 1995) . What, remains unclear is whelher t,he
increase in mort,alit,y is relat,ed Eo a greater sensit,iviEy
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of post-mortem diagnosis, an increase in severity, higher
concentrations of pollut,anEs or environmental E,riggers,
older t,herapeut,ic approaches having a negat,ive impact on
E,he longitudinal course of t,he disease, or whether
inavailability of medical care has worsened ouEcomes
(Weiss & Wagener, 1990).
Fortunat€Iy, severe, Iife-t,hreatening ast,hma is
sti11 relat,ively unconunon; the majority of people who
have the disease experience mild Eo moderate episodes
which are amenable to t,herapy. Of great,est, relevance Eo
the at,hleEic and exercising corrnunit.ies is exercise-
induced asE,hma or, more properly, exercise-induced
bronchospasm (EIB). Bronchospasm t,riggered by physical
exerEion occurs in approximat,ely L0-7-2eo of t,he general
populaEion and in up t,o 90? of persons with asthma
(McFadden, Jt., & Gilbert, L994; Mahler, 1993) . EIB can
dramat,ically reduce pulmonary funcE,ion and Iimit, physical
performance but, appropriat,e t,herapy can bIunt, or
eliminate t,hese handicaps. Due t,o t,he high rat,e of
incidence of EfB in athleEes parEicipating in the 1984
Sarajevo Wint,er O1ympics, the United SEat,es Olympic
ConmiEtee aggressively screened athleEes before Ehe 1984
Los Angeles Sursner Games and found 67 of 597 at,hleles
(11?) affected by asthma or EIB; testing revealed
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pulmonary function declines of 16-35? after exercise in
this group (Mahler, 1993).
Additionally, the airvrays of a pat,ient, wit,h EIB are
especially sensit,ive when underlying asE.hma is acE,ive due
to allergies, respiratory infect,ions or nonspecific,
environment,al irritant,s (cigareute smoke, air pollutants,
eEc. ) , and can remain hlperresponsive even when asE,hma
appears t,o be in good conE,rol (Zawadski, Lenner, &
McFadden, Jt., 1988) .
The process of screening for ast.hma and EIB and
prescribing appropriate E,herapy Eo minimize limiEaEions
in physical performance is straight,forward buE. it, is
important Eo remember t.hat the overall approach to
evaluation and treatmenE of E,hese condit,ions has
undergone monumental change in the IasE, five years. In
the following pages the pathophysiologXl of asEhma and EIB
will be reviewed as well as t,he hist,orical approach to
care and E,he fundamental changes which define the new
meE,hodoloEg for treatment. of E,he asEhmatic paE,ient,.
PATHOGENESIS AIID PATHOPHYSIOLOGY OF ASTHMA
Medium and small airways are t,he primary anat'omic
site of dysfunction in asEhma. Normally, bronchial
diamet,er is adjusEed and conE.rolled by smoot,h muscle
bands which encircle the air:tray. The muscle can relax
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and allow dilat,ion of the airway or contract, and cause
bronchoconstriction. These changes in airvray diamet,er
occur in response Eo changing oxygen demand during
exercise and can proE,ect t,he lungs from irrit,ant,s or
inadeguaEely condiE,ioned (poorly warmed or humidified)
air. The parasympat,het.ic and sympatheE,ic nervous syst,em
have ant,agonistic effects which control t,he smooth
muscle. ParasympaEhetic (cholinergic) st,imulat'ion
triggers bronchoconst.ricE.ion and sympathet,ic (adrenergic)
sE,imulation causes bronchodilat,ion. The direcE neural
control of ainrray diameter is augmenEed by Ehe effects of
circulating cat.echoleamines and neuropepEides (O'Hara,
199s) .
The airways are lined with mucus membranes which
contain ciliat,ed epithelium, mucus producing goblet cells
and specialized inunune cells (mast ceIIs, lymphocyt,es,
neuE,rophils, eosinophils and macrocyt,es) (Rollason,
1995). BeneaEh the mucosa lies a rich vascular bed t,hat
warms and humidif ies inhaled air, proEect,ing E,he alveoli -
The membranes physically Erap suspended part,iculaEe
mat,t,er and EransporL it, out, of the respiratory tract on a
Ehin layer of mucus (mucociliary t,ransport) , and also
provide an irmnunologic rrfront line" of defense against
microorganisms which can invade Ehe body t,hrough Ehe
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tracheobronchial route. In a fashion similar t,o airway
dj-ameter cont.rol, Ehe functions of the lining are also
influenced by Ehe auEonomic nervous system.
Parasympathetic st.imulat,ion dilaEes mucosal blood vessels
and increases mucus producEion while sympat.het,ic
stimulat,ion causes mucosal vasoconsE,rict,ion, increases
ciliary beaE speed, and st,abilizes masE. cells t,hereby
decreasing release of inflanunatory mediaEors (Rollason,
1995) . In sununarT, normal mid- Eo small-sized airways
direcE, and condition inhaled air and proE,ecE against
irrit.ants and microbes by physical removal or inununologic
neutralization. Normal air:ways acconunodaE,e changing
physiologic needs, and prot.ecE. against, environment,al
conditions by bronchodilaEion or bronchoconst.riction.
The ast,hmaEic airway will respond t,o Ewo general
categories of t.riggers. Ext,rinsic asthma (aIso known as
allergic, atopic, or irmnunologic asthma) is triggered
when a specific ant,igen, to which a patienE, has been
previousty seniit,ized, binds to masE ceII surface
inrnunoglobulin E (rgE) and causes ceII degranulat'ion.
DegranulaE,ion releases inflanrnatory mediators including
hisEamine, chemot,acEic factors and leukot,rienes.
Int,rinsic or nonallergic asthma is triggered by non-
antigenic facE,ors such as cold air e:q>osure, exercise,
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stress, irritants, and respirat,ory infections (O'Hara,
1995; Rol1ason, 1995). Nearly all pat,ients have a
combinat,ion of ext,rinsic and intrinsic ast,hma, wiE,h an
allergic component, ident,ified in ovet 2/3 of pat,ient,s
(McFadden, Jt., a Gilbert,, L992; Nacional Ast,hma
EducaE,ion Program Expert Pane1 Report, 1991). Due Eo the
strong correlaE,ion bet,ween elevat,ed IgE levels and self -
report,ed ast,hma symptoms in addit,ional studies, some
researchers cont,end that all asthma has aE, least. some
immunologic component. Even in chi.ldren with no history
of asE,hma or wheezing, measurable air:l,ray hyperreactiviEy
is correlaE,ed Eo elevated serum IgE leve1s, further
suggest,ing a connection to atopy. (Sears eE aI., 1991)
Regardless of t,he E,rigger, asthma exacerbations
generally follow a progression E,hrough aE least. t,wo
phases. Phase I or early phase occurs within 10-30
minuE,es of exposure Lo t,he Erigger and lasEs one to t,hree
hours. MosE notable during E,his early phase is
bronchoconsErict,ion which result,s in a decrease in
airflow (especially expirat,ory flow) (O'Hara, 1995). The
bronchospasm oft,en sponEaneously resolves within 1-2
hours and can begin t,o resolve within minut,es aft,er using
bronchodilat,or medicaLions. On a celluIar and tissue
Ievel, masL cells become ac'tivated and degranulaEe,
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releasing mediators of inflanunat,ion. These mediators act
directly on bronchial smooth muscle and vasculature,
recruit, and act,ivat.e inflanrnatory cells, and can enhance
or suppress E,he ef fect of other mediaEors. They also
promoEe secreEion of mucus which is more viscous t,han
normal while impeding ciliary mucus clearance
(Rachelefsky, t992; McFadden, Jr., c Gilbert,, ]-992) .
This release of mediators is t,he initiating evenE
for the lat,e phase or phase II of the exacerbat,ion which
occurs in Ehe next 2-24 hours and lasEs up to t,hree days.
This phase is marked by a complex and incompletely
understood int.eraction of mediators and inflanmatory
celIs which damage the respiraE,ory t,racE and impair
pulmonary function. VirEually all patient,s experience
lat,e phase inflanunatory changes and 20-60? have
additional airflow obstnrction within 4-8 hours after the
init,ial bronchospasm (Rachelef sky, L992) .
MasE, ceIl mediaE,ors with a rapid onset, of act,ion
include hist,amine and prostaglandin D2 while slower
acE,ing mediaEors (4-8 hour delay) include leukoE,rienes
and plat,elet,-act,ivating factor (PAF) . PAF and
leukotriene D4 (LTD4) are Ehe most, powerful mediat,ors of
airway inflanrmat,ion and bronchospasm (Rachelefsky, L992) .
Alveolar macrophages also have fgE recept,ors and can
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release thromboxanes when act,ivated. Neutrophils and
eosinophils are recrrrit,ed via celI specific chemot,acgic
f acE,ors, leukoE,riene 84, PAF and hydroxyeicosapentanoic
acid, and infilt,rate t,he tissues of t,he air:vray.
AcEivat.ed helper T-ce11s, macrophages and epithelial
cells all produce cyEokines which are chemoEacEic for
macrophages and eosinophils (McFadden & GilberE, L992;
Rachelefsky, t992) . Sensitized by the initial bursE of
mediaEors, t,hese ce11s in turn release additional
arachidonic acid metaboliE,es and chemoEacE,ic factors of
E,heir own.
Eosinophils play t,he most important. rol e of all
inflanrnaEory cells during the laEe phase. They are
present, in great,er than normal numbers in at,opic pat,ienEs
and contain t,he greaE,esE concenEraE,ion of cyE.otoxic
agents (OrHara, 1995; McFadden, Jt., & GilberE, L992) .
When activat,ed, eosinophils release major basic proEein,
eosinophil cat.ionic proE,ein, eosinophil proE,ein-X, and
eosinophil peroxidase. A11 of these prot,eins and enzymes
cause direct, damage to Ehe airvray epiEhelium, affecting
normal secret,ory funct,ion.
EpiE,helial cells also cont,ain neuEral endopepEidase
(enkephalinase) , dr enz).me which limits t,he act,ivity of
manrnalian sensory neuropepEides, y€t anoEher class of
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proinflanunatory mediators. Thus, eosinophil-mediated
epithelial damage int,erferes with normal enzymatic
deactivat,ion of neuropepE,ides and their inflanrnaEory
poEency is enhanced up t,o 100 t.imes normal levels (So1way
& Leff, 1991). BronchospasE,ic neuropepEides are produced
by sensory nerves known as airway C-fibers, and by newly
dj-scovered nonadrenergic, noncholinergic (NANC) aut,onomic
nerves, rather than by inf larnmat,ory leukocytes or
immunologic cells (Barnes, l-989) . Tachykinins
(neurokinins, subsEance P, et,c.) and calciEonin gene-
related pept,ide (CGRP) are Ehe neuropepEides with the
greatest, impacE, on bronchial smooth muscle cont,racE.ion,
vascular tone and permeability and on mucosal secreE,ory
and ciliary transporE, functions (Solway & Leff, 1991).
Epithelial damage also exposes airway C-fibers to direcE
stimulaE,ion by irriE,anEs and ot,her mediaEors (McFadden,
,Jr., & Gi1bert,, 1992; Rachelefsky, L992) .
In surnmary, an antigen-IgE interaction initiaE,es a
release of inflanrnaEory mediat.ors (especially PAF and
Lm4) which have direcE, effecE,s on the airway diamet,er
and mucosal funcE.ion as well as t,he abiliEy E,o aE,E,ract.
and act,ivaEe inflanunaEory leukocytes (principally
eosinophils) . The inflarrnatory leukocyt,es release
addiEional mediators and cyt.ot,oxic agenEs which damage
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E,he epithelium, affect, airvay funcE,ion, per?eEuaEe
inflarmnaEion, and enhance the release and act,ivity of
neuropeptides (Eachykinins being Ehe most, acE,ive) which
possess their own proinf larmnaE,ory ef fecE,s.
The inflarnmaE,ory response sensitizes airways Lo
allergens, nonspecific irritanEs (pollutanEs, cigaret,t,e
smoke, etc.), and respiraE,ory infecE,ions, which can
predispose Ehe paEienE, Eo ret,riggering of phase I
responses. This stage is known as a Phase III or
hl4rerresponsive phase and can persist up t,o 3 weeks afEer
the init,ial E,riggering evenE and acute ast,hma episode
(O'Hara, 1995). Thus, dD asEhmaEic may careen from
exacerbaEion Eo exacerbaEion, each aEEack producing a
smoldering inflanmat,ory response t,hat predisposes t,he
patient, Eo t,he next,, and causing chronic mucosal damage
and subtle airway funcE,ion abnormalities on an almost
cont,inuous basis. Indeed, Ehe mucus plugging, submucosal
edema, smoot,h muscle hl1)ertroPhy, and inflanmat,ory ceII
infiltraE,ion oft,en demonsErat,ed aE, aut,opsy in pat,ients
who have died of acute ast,hma are also documenE,ed in
asympt,omat,ic pat,ient.s diagnosed wiEh mild asE,hma
(Rachelefsky, L992). However, while a few studies do
suggesE permanenE, lung damage can occur over E,ime in some
subpopulaEions of asthmaEics (mosE, have addiE,ional risk
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fact,ors such as cigareEEe smoking), asEhma is generally
noE considered t,o be a progressive disease such as
emphysema or cysEic fibrosis (McFadden & GilberE, L992).
The cascade of inflanrnaEory event,s has only recently
been linked Eo asEhma morbidity and mort,ality, and is the
basis of a new approach to asEhma E,reaEmenE. For E.he
most, of Ehis cenEury, pharmaceuEical t,herapy has focused
aLmost exclusively on t,he relief of bronchospasm, the
most pressing concern when a paEient is dyspneic. Before
moving on to hist,orical and current. concepts of
t.reaEment,, a review of EIB, one intrinsic varianE of t,he
disease, is in order.
PATHOPHYSIOLOGY OF EXERCISE-IIIDUCED BRONCHOSPASM (EIB)
Exercise-induced bronchospasm serves as a useful
model for non-inrnunologic or intrinsic asE,hma. Other
inErinsic asthma triggers include viral respirat,ory
infect,ions, exposure t,o cold air, and nonant,igenic
irrit,ants such as arunonia, cigaret,t,e smoke, and oxidative
pol1uEant,s. Low intensity exercise is ofEen well
tolerat,ed (Wilson & Evans, 1981), buE G-8 minutes of
exercise aE, a level of 80-100? of predicEed maximar hearE
raE,e will usually trigger s)rmpt,oms (Ky1e, Walker,
Hanshaw, Leaman, & Frobase, L992; McKenzie, Mcluckie, &
SE,irling, L9941 . Synrpt,oms may not. be not,iceable or reach
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their peak until 5-10 minutes aft,er exercise is
completed, yet this factor can be especially deErimental
where an interrral of activit,y is followed by a shorE
break and Ehen another period of st,renuous acEivity
(e.9., playing offense in a team sporE) . S)rmpt,oms
usually resolve without treatmenE in 20-30 minut,es, and
much more rapidly if bronchodilat,ors are used.
Pat,ienE,s with unstable or inadequaE,ely E,reat.ed
ast.hma or atopy are mosE, at. risk for EIB. Conversely, iE
j-s usually much less contrnon or severe in pat,ienEs wit,hout
t,hese predisposing conditions (SIy, L985) . ApproximaEely
90? of ast,hmatics and 35-402 of pat,ienE,s with allergic
rhinitis have EIB (Virant, L992; Mahler, 1993) and
antigen exposure has been shown t,o increase EfB
h14>erresponsiveness (Zawadski, Lenner, & McFadden, 1988) .
The physiological mechanism which t,riggers EIB is
the subject of some debat.e. Some evidence suggesEs Ehat
exercise-related h14>erpnea causes airway heat, loss which
E,riggers bronchospasm via Lhermally sensitive
neuroreceptors (Snoddy, Jr., 1995). OE,her evidence
point,s t,o airway drying and mucus osmolarity changes
caused by increased air fIow. Most researchers feel both
of t.hese principle factors contribuE,e to some degree
(McFadden & GilberE, L994; SIy, 1986; EgglesEon, 1985).
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OEher proposed mechanisms of EIB include h14>eremic
vascular respohses during airway rewarming (McFadden,
Jf,., 1990; McFadden, Jt., & Gilbert,, L994) and hypocapnea
(Snoddy, Jr., 1995). SE,iII another t,heory of EIB
eE,iology suggesEs abnormalities of sympathoadrenal
response Eo exercise in asEhmatic subjects. At leasE one
experimenEal sEudy has refuted t,his, demonstrat,ing normal
rises in circulaEing catecholeamines with exercise
challenge (Gilbert., Lenner, & McFadden, 1988).
Whether inflammatory mediators further modify this
response is also unclear (Tay1or, Wel1ings, Taylor, &
Fu11er, 1992) . CoId and hyperosmolar aerosol-induced
bronchospasm does iniE,iat,e release of LTD4, t,hromboxanes,
PAF, and prost,aglandins (Virant, , L992) . The mast, ceII
mediators hisE,amine and neutrophil chemoEactic factor are
found at elevated levels in the plasma of patienEs wit,h
EIB (Egg1est,on, 1986) . In a guinea pig model hyperpnea-
induced bronchospasm and increased bronchovascular
permeabiliEy appears to be t,riggered by t,hermal effects
and moderat,ed by Eachykinins (Garland eE aI. , 1991) . One
difficulty in sorE.ing ouE, Ehe role of mediaE,ors is E,hat,
they have a broad range of effects on different, E,arget,
tissues (i.e., bronchospasm, changes in vascular tone and
permeability) and t,hat t.here is a funcEional overlap and
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interact,ion between differenE, mediators (McFadden, 1990) .
Various st,udies with pharmacologic blockade of mediators
or t,argeE, recepE,ors have yielded mixed results (McFadden
c Gi1berE,, L994; Zawadski, Lenner, & McFadden, 1988).
Another feat,ure unique Eo EIB is a refracE,ory period
after symptoms have occurred and resolved. 40-50? of
people with ErB will remain resistant or less react,ive Eo
the developmenE of new symptoms for one to two hours
after E,heir iniE,ial episode (McKenzie et aI. 1-994; S1y,
1986). The mechanism for the refract,ory period is
unexplained and major flaws exist, in each of Ehe three
major theories (EgglesEon, 1986) . One t,heory suggesEs
that, bronchial smoot,h muscle Eemporarily becomes less
sensit,ive to the ef f ecE.s of proinf lammatory mediaE,ors;
this has been disproven in t.he case of at leasE, one
importanE, mediat,or, hisEamine. Another explanaEion
sE,ates E,hat, physical act,ivity provokes t,he release of
circulat,ing caE,echoleamines which moderat,e
bronchodilat,ion. t'lre problem wit,h t,his Eheory is t,hat,
cat,echolamine levels fa1I to pre-exercise levels within
10-15 minut,es aft,er exercise ceases while the refract,ory
period persisE,s for up to Ewo hours. A third theory
assert,s t,hat, mediaE.ors become t,emporarily depleEed aft,er
t.he initial cascade is triggered. However, only minimal
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amounEs of the mediaEor reserves are released, even upon
maximal st.imulaE.ion, during in vit,ro sEudies (McFadden c
Gilbert,, L994) .
ForEunaE€Iy, EIB is typically mild, resolves guickly
wiE,hout, medicat,ion, and does not usually iniciate
persist,ent, airway h14>erresponsiveness (McFadden a
GilberE, 1994; Zawadski, Lenner, & McFadden, 1988) . No
more Ehan 30-40? of those with EIB exhibit a laEe phase
decline in pulmonary function. This seems Eo occur
primarily in those with delayed recovery from initial
bronchospasm (SIy, 1986) , and may be related t,o more
severe, underlying asthma. AddiE.ionally, st,rat,egically
t,imed induct,ion of E,he refractory period can be used Lo
proEect. an athleEe from performance-limiting symptoms
during compet,it,ion. This non-pharmacologic t,reatment
will be discussed more compleEely during the Eherapy
section of Ehis review.
ESTABLISHING THE DIAGNOSIS OF ASTHIIA:
srcNs, SY-ITIPTOMS AI{D TESTTNG
A thorough medical hist,ory is perhaps Ehe most
useful tool available in establishing a diagnosis of
bronchospasEic airway diseases. United St,at,es Olympic
Comnit,t,ee screening in 1984 ident,ified 90t of t,hose
at,hletes with asE,hma or EfB by quesEionnaire alone (Voy,
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1986). A perEinent history probes for classic symptoms
of asthma such as frequent or persist,ent cough, wheezing,
dyspnea or chest tightness related t,o exposure to
allergens, irritants, or cold air. Exercise, respiraEory
infect,ions, and medications (especially nonsteroidal
antiinflamnaEory agenEs and B-adrenergic blockers) are
other comrnon triggers. It. should be remembered t,hat,
patienEs are ofE,en unable Eo accurately raEe the severit,y
of airway obstruction, even in near-faE,a1 episodes
(Rollason, L995; Kikuchi et, d1., L994) , perhaps due to
abnormal caroE,id chemoreceptors which are unable Lo
perceive h14>oxia.
It is also useful Lo determine Ehe pat,tern of t,he
disease: a seasonal or allergen-triggered exacerbation
can suggest at,opic disease and frequent nocturnal
symptoms suggest more serious inf larmnation. The pat,t,ern
of individual exacerbaEions (prodrome, duraEion, need for
and frequency of medicaE,ion use, response to EreaEment,
and out,come) can also help esLablish overall severity
(Mah1er, 1993; NaEional AsE,hma Education Program Expert,
Panel Report,, L991) .
Some gross indicaEors of t,he impacE, of t.he disease
can be determined by the number of emergency deparEment
visits and hospitalizat,ions, Ehe number of near-fat,al
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exacerbations, the number of episodes requiring
t,herapy such as int.ubation, oral or parenteral
and t,he degree of int,erference t,he pat,ient. has
int,ensive
steroids,
experienced wiuh normal physical acE,ivities, school, or
work (NaEional Asthma EducaE,ion Program Expert Panel
Report, 1991). A family history or personal history of
atopy (a1Iergic rhinitis, eczema, recurrenE, sinusit,is,
nasal polytrlosis) or a previous diagnosis, or suspicion,
of ast.hma may help clarify E,he diagnosis. PasE, or
currenE, use of anEihist,amine or aI1erg-y medicaE,ions , ot
use of bronchodilat,ors (whet,her purchased over-the-
counEer, borrowed from an acquaint,ance, or by previous
prescription) is also an import,ant, diagnost.ic cIue.
Fina11y, it is always useful Eo know if t,he patienE's
home or work environment, contains allergens or irrit,ants
which t,rigger symptoms (e9., indust,rial chemicals, pets,
allergen-harboring furnishings such as caryeE,s or
draperies, wheE,her the paE,ient smokes or is exposed t,o
secondary cigaretE.e smoke, eE,c.) (Nat,ional AsE,hma
Education Program Expert. Panel Report, 1991).
Physical examinat,ion by a healt,h care provider may
reveal findings consistent, with ast,hma, especially during
an acut.e moderat.e or severe exacerbaE,ion, but persons
with mild disease or who are in a quiescent period
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between exacerbat,ions may appear remarkably well and yet,
still have inflamed, hl4rerresponsive airways. Mildly
abnormal physical findings include wheezes and ot,her
advent,itious breath sounds and a prolonged expiraEory
phase during breat,hing. Signs of more severe disease
include use of accessorT muscles of respirat.ion,
supraclavicular and intercostal reE,ract.ion wiE,h
inspiraE,ion, changes in ment,al sEaEus (hypoxic agit,aEion,
sEupor or unconsciousness), and cyanosis. Wheezing may
acEualIy disappear in severe airway obsErucEion if t,he
pat,ient, is unable Eo move enough air Ehrough E,he
respiraE,ory Eract t,o produce abnormal breath sounds.
Sympt,oms of associated atopy can include swollen, bluish-
red nasal mucosa, increased nasal discharge, nasal
polyps, conjuncE,ival inflarmnaEion and eczema (Mah1er,
1993; National AsEhma EducaEion Program Expert Panel
Report,, 1991).
Laboratory t,esEing centers on pulmonary function
tests (PFT's) , measured by spiromeE.r?, and peak
expiratory flow rat,e (PEFR) . These examinaEions documenE
the rate and volume of air movement aE. st,andardized
poinEs in t,he respiraE,ory cycle. Specif ic measurements
pert,inenL to the asthma workup include forced expiratory
volume at 1 second (FEv 1), and forced vital capacity
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(FvC, t,he total air volume which can be rapidly and
forcefully exhaled). Decreases in FEV 1, FVC and FEV
L/FvC rat,io which are reversible wit,h medical t,herapy are
diagnostic of asEhmat,ic airway obstnrct,ion (Mahler,
1993) . Maximal mid-expirat,ory flow rat,e (MMEFR), also
known as forced expiratory flow raEe between 25? and 75t
of vit,al capacity (FEF 25-75*) , and peak expiratory flow
rate (PEFR), which measures maximal airflow speed during
forced expiration, are arguably the best measures of
smalI and medium-size airway funcLion. These tesE,s can
reveal funcE,ional changes at t,he anatomic site of most,
concern in asthma. PEFR, which correlat,es well with FEV
L, has Ehe added advanE,age of being easily and accurately
measured by the patienE, with an inexpensive device known
as a peak flow met,er. AfE,er the diagnosis of asEhma is
established, PEFR is a very useful met,hod of monit,oring
t.herapeut,ic progress (Mahler, 1993) . Tracking of E,rends
in PEFR values is now routinely reconunended for paE,ient,s
who have moderat,e or severe ast,hma (Nat,ional AsEhma
Education Program E:<pert, Panel Report,, 1991). PEFR alone
should not, be used as a diagnosE,ic E,esE for ast,hma
however because abnormalities in PEFR measurement,s can be
due E,o oEher fact,ors such as poor Eest, execuEion, weak
effort, or resErictive lung disease. IE should be not,ed
50
―
|
APPEIIDIX A (Continued)
E,hat, PFT's may be normal or only mild1y abnormal between
exacerbations and Eherefore negative Eest,s do not,
conclusively rule out, ast,hma (Voy, 1985). Serial EesEs,
E,est,s during acuE,e exacerbaE,ions, or bronchoprovocat,ion
EesEs may be necessarlf to esEablish t,he diagnosis.
Additional tesEing may include blood work (absolute
eosinophil counEs >250-4OO cells per cubic miltimeter are
corlmon in both intrinsic and extrinsic asthma) (OtHara,
l-995; Barnes, 1989), chest x-ray sEudies t,o rrrle out,
other infect.ious, cardiovascular, or pulmonary
conditions, and allergry EesE,ing t.o confirm aEopy.
Bronchoprovocation Eests with inhaled methacholine or
hist,amine, or via a sEandardized exercise proEocol may be
required Eo evaluate paEienLs with an unclear patt.ern of
sympt,oms.
DIAGNOSIS OF EXERCISE-IIIDUCED BRONCHOSPASM
Since Ehe vasE, majority of people who have EIB also
have the underlying disease of asLhma, the evaluation of
the paE,ienE wiEh'suspect,ed EIB begins wit,h exactly t.he
same assessment, process described in Ehe previous
sect,ion. The same medical hist,ory, physical examinat,ion,
and baseline Eest,ing can help est,ablish Ehe diagnosis.
Great,er emphasis should be placed on sympE,oms related E,o
physical activity, remembering that, more strenuous
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act,ivity t,ends t,o provoke more severe bronchospasm
(Mahler, 1993; Wilson & Evans, 1981) . Persist,ent, cough
during or after exercise (somet,imes referred to as
"Iocker room coughing") st,rongly suggesEs EIB as does
dyspnea-limit,ed performance in an other:vrise well Erained
individual (KyIe et, aI. , L992) . The t14>e of activity and
t.he environmenE in which symptoms occur can also point t,o
EIB. H)T)erresponsivity is Eriggered more easily by
breathing dry, cold air (e9., running outdoors in winter)
and is more 1ike1y with running than with swinming, even
under similar environmenE,al condit.ions and meEabolic
demand levels (Bar-Yishay eE dI., 1982) .
The "goId standard" of evaluaEion for EIB is the
exercise challenge test (Kyle et dI. , 1-992; Nat.iona1
AsEhma Educat.ion Program ExperE, Pane1 ReporE, 1991).
Although less sensit,ive for t,he evaluation of extrinsic
asE,hma than meE,hacholine challenge, iE. is more specific
for EIB (Mah1er, 1993). Six t.o eight, minut,es of
sE,renuous treadmill running at 85-908 of predicted
maximal heart. rale is usually sufficient, Eo induce EIB
(proEocols typically use 10t grade at 4-6 MPH to raise
heart, raEe t,o t,he desired range) (Ky1e eE dI., L992;
Mahler, 1993) . Baseline (preexercise) spiromet,ry and/or
PEFR is measured and compared t,o values assessed every 3-
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5 minutes af ter E,he exercise is complet,ed. It is
suggesEed that Eesting cont.inue for a total of 15-30
minutes although in mosE, cases maximum declines in PFT's
occur within five minut,es afEer t,he challenge (Freed,
Bromberger-Barnea, & Menkes, 1985). Even normal subjecEs
may experience minor abnormalities in pulmonary funct,ion
test,s aft,er exercise (Chapman, AIIen, & RomeE,, 1990), so
a posiE,ive Eest is defined as a drop in FEV 1 or PEFR of
>10t compared to preexercise IeveIs. Declines of l1-25e"
are rated as mild EIB; 25-35% changes are considered
moderate, 35-50? moderaE,ely severe and a decline of >50?
is raLed as severe EfB (Kyle et dI., 1,992) . Once the
diagnosis of EIB is established and appropriat,e t,herapy
initiated, follow up test,ing is recommended Eo moniE,or
progress unt,il t,he exercise-relat,ed PFT changes are
limit,ed E,o less than half of t,he original decline.
ASTHMA THERAPY
For nearly a century asthma therapy focused on
retief of bronchoconsErict.ion and t,he inflanrnaEory
componenE of Ehe disease was deemphasized (Kniker, 19941.
In large parE, t.his result,ed from the Eherapeutic options
available. During Ehis period Ehe most, pot,enE and
specific ast,hma medications available were meE,hylxanE,hine
bronchodilaEors (caffeine, t,heophylline, t,heobromine)
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which provided perceptible relief from ainray obst,rucEion
(Ra11, 1990). It was noE unE,il t,he 1950's thaE, t,he
benefiEs of antiinflamnat,ory medications were recognized
and applied Eo asthma t.herapy (Li & Reed, 1989) .
UnforEunat.ely, Iong Eerm use of oral sE,eroids is
associated with serious side effects including
gasE,roinEestinal ulceration, caEaraeE formation, bone
growt,h and mineralizaE,ion abnormaliE,ies, glucose
intolerance and diabetes. Additional side effecE,s
include skin atrophy, irmnunosuppression, body fat
redistribution result,ing in facial and Eruncal deformity,
h14>ertension and suppression of the hypot,halamic-
pit,uitary-adrenal (HPA) axis (Medica1 Letter, 1995; RaIl,
1990). Due t,o E,hese side effect.s oral sEeroids were
reserved for patienE,s with the most, severe and unsE,able
f orms of asE,hma. Epinephrine was used f or serious
exacerbations of asthma, and while it, serves as a
powerful bronchodilat,or (by stimulat,ing B-adrenergic
recepEors), it has an equal amounE, of a-adrenergic
stimulation, which causes vasoconscricEion, increases in
cardiac workload and myocardial oxygen demand,
dysrryE,hmias, and hyperE,ension (Medical Economics DaEa
Product,ion Company [Medical Economics] , 1995) .
AnE,ihisE,amine dnrgs were sometimes prescribed t,o conE,rol
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the atopy conmonly associated with asthma buE, t,he
anticholinergic side effecE, of drying and t,hickening
respiratory secreEions (already abnormally viscous) and
the sedaEion associaEed with early versions of t.his class
of medicat,ion of t,en limited their usefulness.
The 1960's and 1970's saw the inEroducEion of new
aerosol bronchodilators and the khellin-derivaE,ive
cromolyn sodium (Int,al, sodium cromoglycaEe in Europe).
The newer bronchodilators had a greater affinity for the
B-adrenergic receptors and caused fewer cardiovascular
side effecE,s. Cromolyn sodium has a mechanism of action
which is sti1l not clearly defined, but. ic is thought to
work by sEabilizing masE cells, pr€v€rt.ing E,he
degranulaE,ion process which releases proinflanmat.ory
mediators.
By t,he 1970rs and 1980's inhaled aerosol St,eroids
had come int,o limiE,ed use for pat,ient.s with severe
asthma. These agent,s were considered t,o be nearly E,he
1ast, step in t.herapy (short of placing pat,ients on oral
st.eroids) because concerns existed regarding pot,ential
steroid side effects in long term use, and also because
the imporEance of conErolling inflanrnat,ion had not, been
fully recognized. There ast,hma treatment, remained,
having
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made progress toward more effect,ive and specific
bronchodilators and reserrzing anEiinflarnrnaEory
glucocort,icoids for E,he most, seriously ill asE,hmat,ics.
In the 1aE,e 1980's and throughout t,he 1990rs,
monument,al changes occurred in the underst,anding of
asthma and t,heories of Ereatment. While invest,igaE,ing
the increasing incidence and mortality from asEhma,
medical researchers discovered the striking inflanunaEory
changes associated with fatal and near-faEal
exacerbaEions and went on to documenE, t,he same changes in
pat,ienE,s who had only mild or moderate disease
(Rachelefsky, 1992) . InflarnrnaE.ion came to be regarded as
a uniform feat,ure of the condition. PhysiologisEs and
biochemist.s uncovered Ehe myriad effects and int.eracEions
of proinflammatory mediators such as eicosanoids and
neuropepCides. The safety of inhaled glucocorEicoids was
established and forms of Ehe medicaLion were developed
which minimized side ef fecE,s.
The change in our understanding of ast,hma was so
profound t,haE, a select, corrnit,t,ee of asEhma experts was
convened by t,he Nat,ional InsE,itutes of Healt,h in 1991.
They issued a seE, of recontrnendations for Ehe care of
asthma paE,ienE,s which has revolutionized therapy. Before
moving on to Ehe specific applications of these
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recofltrnendations, 6tD overrriew of medications and
nonpharmaceut,ical EreatmenEs is useful .
PHJ{RMJICEIITI EAL AGEMTS
B-adrenergic agonist,s
As previously discussed, sEimulaEion of 82-
adrenergic receptors in the respirat,ory tract. causes
relaxat.ion of bronchial smoot,h muscle and relieves airway
obsEruction. Currently, aerosol E}2-adrenergic receptor
agonisE,s (B-agonisE,s) are the most. widely prescribed
medicaE,ions for asE,hma and are oft,en sufficient as
monotherapy for occasional episodes of mild ast,hma. The
primary advant.ages of these medicat.ions are -
effectiveness, rapid onset of bronchodilaE,ion,
cardioselectivity (target,ing of bronchial recept.ors and
minimizing pot.enE,ially dangerous cardiovascular side
effects), reasonable cost, and duration of effect 14-12
hours) . AddiE,ionally, alt,hough t,hese medicat,ions are not,
promoE,ed as such, B-agonist,s are powerful st,abilizers of
mast, cel1s, which have surface B-adrenergic recept,ors.
They are,in fact, many times more pot,enE than the mast
cell-stabilizing agenEs cromollm and nedocromil which are
market,ed specifically as drugs which can prevent,
degranulation and m6diator release (Page, LggL; Cheung,
Tinuners, Zwinderman, BeI, Dijkrnan, & SEerk, L992) .
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Included in t,he B-agonist caEegoqf of medication are
aerosol albuE,erol sulfaEe (salbutamol in Europe),
sa1meEerol, Eerbut,aline, pirbuterol, bit,olE,erol,
isoproE,erenol, and meEaproterenol . AlbuE,erol is E,he most,
widely prescribed medicaEion, and salmeEerol, t,he mosE
recently released B-agonist, has E,he advantage of up to
L2 hours of acE,ion per dose (most others must be t,aken
every 4-6 hours) (Peartman et. dI., 1992; Cheung et, dl.,
L992). Side effects of B-agonisL,s include headache,
Eremor, tachycardia, gastrointest.inal upset, and
nervousness. OraI forms of many of t,hese medicat,ions are
available but are less effective; have a slower onset of
acEion, and a greater incidence of side effect,s (Medical
Letter, L995). Questions regarding E,he safet,y of t,hese
agent,s have recent,Iy been raised due E,o an association
beEween large, frequent, doses and fat,aI or near-fat,al
asE,hma (Executive Conunitt.ee, American Academy of Allergy
and Inununologiy, 1993; Page , L99L; Spitzer, 1992) .
Whether this associaEion is acEually caused by regular
doses of B-agonisEs, or Ehe increased use of t,hese dnrgs
represenEs a marker for worsening or unst,able disease is
a maE,E,er of debate and several Eheories have been
proposed Eo explain t,his connect,ion.
One finding which suggest,s t.hat, the medicaEion is
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the specific cause of greater morbidity and mortality is
t,hat a greaE,er degree of airway hy;lerresponsiveness has
been demonsE,raEed after prolonged use of B-agonists
(especially so af ter sudden cessat,ion) (Sears eE aI. ,
1990; VaEhenen, Knox, Higgins, BriE,Eon, & Tat,t.ersfield,
l-988) . Wit.h regular bronchodilator use, B-recepE,ors may
become less responsive t,o normal physiological or
prescribed pharmaceutical int,erventions t,o relieve airway
spasm (Vat,henen, Knox, Higgins, Brit,ton, & TaE,Eersfield,
1988) . OEher studies, however, refut,e B-agonist-induced
hlperreacEivity or functional declines (Execut.ive
ConuniEt,ee, American Academy of Allergy and Immunology,
1993). Anot,her t.heory suggests cardiovascular side
effecE,s of t.hese medications may be implicat,ed in faEal
episodes, especially with more potent and less
cardioselective agents such a fenoE,erol, an agent not,
available in the UniEed SEat,es (Spitzer, L992; Wong,
Pavord, WilIiams, Brit,t,on, & TaEE,ersfield, 1990) . A
E,hird h14>othesis is that pharmaceutically-enhanced
bronchodilaton in an allergen or irritant laden
environment, defeat,s a normal, prot,ecEive
bronchoconsEricE,ive response, allowing greaEer elcposure
Eo offending triggers and a more severe phase II
inflanunatory response (Page, L99L; Executive Corunit,E,ee,
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American Academy of Allergy and lrmnunology, 1993).
The opposing view suggests E.hat, B-agonists do not.
cause increased morbidity or morE,alit,y, and t.hat paEienEs
requiring large, frequent, doses of bronchodilators
(defined as using more Ehan one canist,er per month,
equivalent to approximately 200 acutuat,ions or "puffs"
per monEh) have severe, unstable asE,hma. Proponents of
this view feel that, Ehe increased medicaE,ion demand is a
reflecE,ion of worsening asEhma sEaEus rat.her t.han a
destabilizing factor (Spitzer, 1-992; National Asthma
Education Program ExperE, Panel ReporE,, 1-99t; Executive
Commit,tee, American Academy of A11erg11 and fnrnunologTll,
1993) .
St,eroids
As previously mentioned, glucocorE,icoid treatmenE,
had for many years been relegat,ed t,o Ehe t,hird or fourth
line of defense for patient,s with severe asEhma. Due to
t.he new emphasis on healing IaE,e phase air:vray
inflarnmat,ion, certain forms of sEeroids are now
recontrnended earlier and for milder cases of asthma Ehan
ever before. MainEenance t,herapy with inhaled steroids is
current,Iy considered t,he mosE, effect.ive firsE, line
Lherapy for moderate and severe asEhma (Kaliner, 1990)
especially since E,he aerosol form is deposiEed direct,ly
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inE.o the inflamed airways wiEhout significant syStemic
absorpEion or side effeccs (UEiger, 1993). Some research
suggesE,s Ehat, initiat,ion of inhaled steroid t,herapy in
even miId, newly diagnosed asEhma is as effecE,ive as B-
agonisE,s (HaahE,ela eE dI. , 1991) .
Glucocort,icoids exhibit a number of acEions
beneficial Eo t,he inflamed airway (Kaliner, 1990) . wit,h
regular use, B-adrenergic receptors increase both in
number and sensiE.iviE.y. MasE celI numbers are reduced and
degranulat,ion is inhibited while hisEamine and eicosanoid
production are reduced. On a functional level, airway
h14>erreactiviE,y, mucus secreEion, and mucosal edema are
all blunted. In short,, a broad range of cellular and
tissue changes associaE,ed with airway inflanunation are
diminished. Tolerance does not, develop with conEinued use
of aerosol st,eroids (UEiger, 1993) .
Side effecEs of inhaled glucocort.icoids are
generally limiE,ed E,o dysphonia (voice changes,
hoarseness, etc.) and oral candidiasis (Ehrush), dD
overgrowEh of fungi oft,en presenE, in t,he oropharlmgeal
flora. These side effect,s are due to deposition of large
aerosol particles in t,he mouE.h and t,hroaE, which can be
minimized by proper meE,ered dose inhaler (l,lDI) technique
and rinsing the mouE,h after Eaking medication (Utiger,
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1993; Kaliner, 1993). DisconEinuaEion of t,he medicine or
treatment of candidiasis wit,h antifungal lozenges for a
short t.ime is only occasionally necessary. Significant
sysEemic effect,s from aerosol steroids do not, occur aE
normal doses due Eo t,he combinat,ion of topical potency,
low absorption, and rapid meE.abolism of E,he medicaEions
(Ka1iner, 1990; Szefler, 1991; Li & Reed, 1989). No
pattern of clinically significanE, derangemenE, of HPA axis
function (Kaliner, L993; Szefler, 1991), abnormal bone
growth or density (Medical Letter, L995; Le bourgeios,
Benoist,, d€ BIic, Allaire, & Scheinmann, 1993), or
adverse epithelial sEnrcture changes (Uuiger, 1993) has
been ident.ified aE recontrnended doses. High dose aerosol
corticoids may puE pacienE,s at, risk for side effect,s
previously discussed, however.
Aerosol sE,eroids current,ly available in t,he United
SEat,es include beclomethasone dipropionaE,e, t,riamcinolone
acetonide, dexamethasone sodium phosphat,e, and
flunisolide. Flunisolide has unique pharmacokinetics wit,h
t,he shorE,est half-life of all t,he lisE,ed agenEs (1ess
than t,wo hours) , rapid hepatic firsE,-pass met,abolism of
sysEemically absorbed medicat,ion t,o a much less acEive
form (Szef1er, 7-99L) , and sustained Eopical act,ivit,y
which allows a L2 hour (Ewice a day) dosing regimen.
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Compliance plays a major role in the success of any
t,herapeutic plan, especially with aerosol glucocorticoids
which exhibit a slow onset of acE,ion. PaE,ient educat,ion
should sEress Ehat these medicaEions have no irmnediate
bronchodilating effecE,, and musE be taken on a daily
basis as maintenance E.herapy E,o heal airvray
abnormalities. A Ehorough explanation of t,he risks and
benefit,s of Eherapy as well as t,he dangers of chronic,
undert.reat,ed asthma can help t,he pat,ient, betEer
undersE.and t,heir disease and the value of complying with
E.reatment (Szef ler, L997-; Li & Reed, 1989) . Many people
have serious concerns regarding t,he use of st,eroids and
iE is import,ant, Eo emphasize t.hat these agents differ
from anabolic sEeroids, that. aerosol preparations have
minimal syst,emic acEivit,y, and that numerous sEudies have
demonsE,rat,ed their saf ety even wiE,h prolonged use.
Oral steroids (typically prednisone, prednisolone
and meE,hylprednisolone) have an import.ant role in t,he
treatment, of chronic, severe asthma resisE,ant to ot,her
therapy, as well as serious, acute exacerbations. Long
Eerm t,herapy with sysE,emic st,eroids runs the risk of
serious side effect,s and the lowesE, possible maintenance
doses should be prescribed for chronic disease,
preferably using a Iow, alt,ernat,e day dosing regimen.
― _
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AcuEe asE,hma exacerbations requiring t,reatment in a
medical office or hospital seEting oft,en require short,
(7-10 day) t,apering doses of oral steroids to speed
resolution and minimize relapse (Chapman, Verbeek, whiEe,
& Rebuck, 1991).
Ktrellin derivatives
Cromolyn sodium and nedocromil are promot,ed as mast
cell st,abilizers and are EhoughE to prevent, degranulat,ion
and release of proinf larmlatory mediat,ors; because of Ehis
effect, Ehey are sometimes classified as antiinflamnatory
agents, although t.his is open t,o some debate. They are
noE, as unif ormly ef f ective as B-agonist.s. IE, appears t,haE,
khellin derivatives are mosE useful in mild Eo moderat,e
ast,hma (Szefler, 1991) and for EIB; t.hey have no act,ive
bronchodilatoiy acEion (Medical Letter, 1995). Side
ef f ect,s are primarily IocaI, wit,h pat,ient,s rarely
reporting slight, throat. irritation, and systemic toxicity
is vircually nonexisE,ant. These agent,s are among the most,
benign pharmaceuEicals used in modern medicine and t,he
excellent, safety profile is one of t,heir great,est
advantages (Medical Economics, 1995) .
Spacers and MeEered Dose Inhalers (ltlDl I s)
No discussion of aerosol medicaLions is complet.e
wiE,houE, a review of the inhalers which deliver t,hem and
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of spacer devices.
MDI's are sealed, pressurized canisE,ers cont,aining
medication which is suspended in a propellent, (usually
chlorofluorocarbon-based) . When acEivated, a precise
amount, of medicaEion is sprayed out of Ehe inhaler
mouthpiece for inhalation by Che pat,ient,. Hiscorically,
healt,h care providers inst,mcEed paE,ient,s t,o t,ighE,ly seal
their lips over E,he mouthpiece and forcefully inhale
during acEuat,ion of Ehe MDI . It, has been recent.l-y
confirmed that, this E,echnique actually decreases the
amount, of medication reaching the lungs due E,o increased
impact and deposition of aerosol on oropharyngeal
surfaces (Lee & fngbar, 1992). This method also requires
a high degree of hand-breathing coordination which many
patienEs cannoE, mast,er.
The currently reconunended technique involves t,ilting
the head backward slighE,ly to straighE,en E,he naE,ural
curvaEure of the post,erior-inferior oropharTnx, opening
t,he mouth widely, and holding the inhaler mout,hpiece
approximately 4 cm in front, of t,he lips (no 1ip seal or
closure around the mout.hpiece is required) . The MDI is
acEuated and t,he paEient, inhales a slow (25-30 liE,ers per
minute flow rat,e), deep breat,h. The breat,h is Ehen held
as long as is comforE,able for t,he patient,, allowing the
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medicine to deposit on t,he airvray mucosa. This met,hod
of f ers several advantages: less hand-breat,hing
coordinat,ion is required, and the large (5-10 mcm)
particles which would normally be deposiEed direct,ly on
the t,ongue and oral mucosa guickly set,t,Ie ouE, and are not
inhaled. Sma11 (L-smcm) part,icles suspended in E,he air
space direct.ly in fronE, of E,he mout.h are inhaled and flow
smooEhly down a somewhat, sCraight,ened oropharynx, without
high speed impact, and deposition on E,he mucosa; more
medicat,ion is delivered to t,he small airways where is has
the mosE, effect (Li & Reed, 1989).
A device known as a spacer can also be used E,o
improve MDI efficiency. EssenEially a hoIIow Eube with a
mouthpiece on one end and a port, which accepE,s inhalers
on the oE.her, spacers have been shown to nearly double
Ehe effectiveness of medications and reduce side effects
(Li & Reed, 1989; Nat,ional AsE,hma Education Program
Expert Panel Report, 1991). When t.he MDI is actuaEed and
t,he dose enE.ers t,he holding chamber, Iarge part.icles
setE1e out, quickly and t,he propellant evaporat,es. The
paE,ient, can Ehen inhale E,he medicaEion wit,hout, regard to
hand-breaEhing coordinat,ion. Decreased incidence of oral
candidiasis and adrenocort.ical hormone abnormalities are
documented benefits of using spacers wit,h aerosol
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sE.eroids (Li & Reed, 1989) ; one brand of spacer
(Aerochamber, ForesE Pharmaceutical) has been shown to
reduce oropharyngeal dnrg deposition from 65-70t of Ehe
delj.vered dose per puff Eo 4-6.5?.
In general, modif ied MDI technique and t,he use of
spacers can improve delivery of medication and reduce
poE,enEial side ef fects. They are nov, routinely
recommended in the care of patients requiring aerosol
therapies.
Theophylline
Theophylline, drr oral met,hylxanthine bronchodilator,
had been the foundation of asthma t.herapy for many
decades. The benefit of effect,ive bronchodilation was
offset. by serious Eoxicity and a narrow range of
therapeutic effecEiveness". Low serum concenEraEions
provide 1it,E1e Eo no symptomaE,ic relief , normal
therapeutic leve1s can cause nausea, headache,
nerwousness, and insomnia, 
.and concentraEions greater
than 20 mcg can result, in seizures, t,achycardia, and
arryE,hmias (Medical Letter, 1995) . Due E,o t,he risk of
serious adverse reactions, regular moniE.oring of serum
dnrg leveIs is required in pat,ients who use this
medication. Theophylline also int,eracts wifh a number of
conrnonly used medicaE,ions including macrolide and
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quinolone anEibiotics, sympathomimet,ics, phenyE,oin,
liLhium, cimetidine and oral conEracept,ives; smokers
met,abolize Ehe medicaLion more rapidly and require
addit,ional dosage adjustmenEs. with t,he availability of
less Eoxic and more poE.ent, bronchodilat.or. medicat,ions and
t,he new emphasis on conErol of the inflanrnaEory component
of asE,hma, E,heophylline has shifted from being a first
Iine E,herapeutic agent to being an adjunct,ive t,hird or
fourth line t,herapy for patienE,s with disease
unresponsive Eo other t,reatmenE,s (Se1f & Ke1so, 1995).
Miscellaneous pharmaceutsicals
Several other medicat,ions play a minor role in
control of severe, complex cases of asthma. Ipratropium
bromide aerosol is an atropine derivat,ive which blocks
int,rinsic vagal tone, relaxing airway smoot,h muscle and
causing bronchodilation. IE is a slow acting, relat,ively
weak agent, and although somet,imes prescribed for severe
airway obst,rucE,ion, it, has 1it,t,Ie t,o no demonst,rat,ed
effectiveness in t,he rouE,ine management, of ast,hma
(NaEional Asthma EducaE,ion Program ExperE, Panel Report,,
1991) . GoId salt,s and meEhotrexat,e, powerful and toxic
medicaEions with demonstrat,ed antiinflamnaEory effect,s,
have been used on an experiment,al basis for severe,
otherwise unresponsive disease. Data on pat,ient selection
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criteria as well as risks and benefit,s are sEil1 being
gathered and analyzed, and the role these medications may
play in t,he E,reaEment, of asEhma is current,ly unclear. At
least, two leukot,riene inhibitors, designed t,o block t,he
act,ivity of t,he most, influential inflanunatory mediaE,ors
at work in asthma, are in developmenE,. Zileuton (AbboEE)
has been recorunended for approval for market.ing by a
United Stat,es Food and Drug AdministraE,ion advisory panel
(Physician Assistant,sr Prescribing Reference L994), and
Zeneca Pharmaceuticals is developing Ehe leukoEriene
recept,or ant,agonist, zafirlukasE, (Acco1ate) (Excerpta
Medica, L995).
In surnmary, aerosol 82-agonist, bronchodilat,ors are a
mainst,ay of asE,hma Eherapy, reversing t,he key sympt,om of
dyspnea. Aerosol corticosteroids have recently emerged as
a primary t,herapy for pat,ients who have more t,han
occasional, mild s)rmpt,oms and t,hese drugs address Ehe
inf lanunaEory basis of t,he disease. Cromollm sodium and
nedocromil prevenE initiation of Lhe inflamnatory
response by st.abilizing mast cells and can be used
preventatively f or bot.h aEopic and int,rinsic asEhma.
Theophylline, formerly a first line t,herapy is now
reserved for paE,ients with severe, unstable asthma
resistant t,o corE,icosEeroids, B-agonists and cromolyn;
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t,he risk of serious toxicity and dnrg int,eract,ions limit
its usefulness. Adjuncts such as ant,icholinergics, gold
salts, and meE,hotrexat,e are used on an experiment,al basis
for t,he very severe asEhma, and new mediat,or-blocking
agents are being developed for future release.
Nonpharmaceutical Approaches to Treatment
The primary nonpharmacologic therapy available to
asEhma pat.ient,s is avoidance of t,hose triggers which
initiat,e syrnpE,oms for an individual. This can include
limiEing exposure to allergens (pets, house dusE,
pollens, eEc.), nonspecific irritant,s such as cigarette
smoke and indust,rial chemicals and avoiding sErenuous
exercise in co1d, dry environments. For persons unable to
avoid a given t,rigger, alternat.ive Eechniques may be of
heIp. At,opic pat,ienE,s may find irmnunoEherapy ("a1Ierg-y
shots") helpful. Cert,ain housecleaning and decorating
sE.raE,egies such as use of high efficiency air filt,ers and
vacuum cleaners, limiting cigarette smoking in living
quart.ers, avoiding use of carpet,ing and draperies, not
allowing pets in the household, and keeping indoor
humidit,y levels low t,o suppress fungal and dust, mit,e
growt,h can reduce exposure to offending triggers. These
methods are oft,en underut,ilized however as many pat.ient,s
would raEher endure asthma exacerbat,ions t,han part, with a
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beloved p€t, redecoraEe, or st.op smoking. These
technigues should always be considered a st,art,ing poinE,
for t,herapy since t,hey can prevent exacerbat,ions, have no
side effect,s, and oft,en provide marked sympt,omat,ic
relief.
STEPPED CARE: A PRACTTCAL APPLICATION OF ASTHI,IA THERAPTES
The 1991 National Institut,es of HealE,h "Guidelines
for Diagnosis and Management of Asthma'r provides a clear
framework for the t,reatment of E.his disease. In t,he past,
therapy was often pased on subjecE.ive crit,eria, wiE,h the
paEients percepE,ion of dyspnea being used as E,he main
indicaEor of status.
Today a combinaEion of sympt,om frequency and
objecEive measures of severiEy guides therapeutic
management,, and allows Ehe raEing of ast,hma as mi1d,
moderate, oE severe. The goal of all t,herapy is t,o
prevenE syrnpE,oms, preserve pulmonary funcE,ion and
physical acE.ivity level aE, near normal ranges, prevenE,
recurrenE exacerbations, and minimize side effecEs from
medications.
Mild ast,hma is defined as int,ermitEenE,
t,imes per week) Iasting less Ehan one hour,
hour) exefcise-related symptoms, infrequenE
month) nocturnal sympt,oms, and asyrnpt.omat,ic
sympt,oms (<2
brief (<L/2
(<2 t.imes per
periods
7t
-l
APPENDIX A (CONTiNUEd)
between exacerbations. PEFR and FEV 1 measurement,s faII
in the range of 80-1003 of predict,ed values with
variat,ions of 20* or more during exacerbat,ions. Avoidance
of t,riggers and prophylact,ic B-agonist,s and/or cromolyn
or nedocromil can often prevent symptoms, and when
sympEoms occur, Eherapy with short acting B-agonists (z
puffs every 3-4 hours) is sufficient. to provide relief.
If exacerbat.ions are relieved and. stat,us is stable, rIO
furE,her Eherapy is generally needed for mild asthma. More
frequent. syrnpE,oms or incomplet.e relief with treatment are
indicat,ors of moderate asthma.
ModeraE,e asthma symptoms occur >L-2 E,imes per week
and may be severe enough t,o disrupt, acE,ivit,y and sleep.
Exacerbations may persist. several days; emergency care is
only rarely necessarlf. PEFR falls within a range of 60-
80? of predict,ed or personal besE results, and may vary
up Eo 20-30t during exacerbat,ions. Therapy for moderat,e
asthma is based on daily aerosol corE.icost,eroids Eo
relieve inflarrunaEion combined with aerosol, shorE-acEing
B-agonisE,s as needed up t,o four times per day to relieve
acuEe bronchospasm. The bronchodilaE,or is considered a
supplemenEal'rrescue" agenE, (Kerstjens, L992; Kaliner,
Mart,in, OtByrne, & Wiedemann, L9921 .
Khellin-based dmgs may also be of use in
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sEabilizing moderaEe ast,hma. If this regimen provides
adequate control (s)rmptomaEic relief, near normal PFTs,
decreased frequency of exacerbaE,ions and decreased need
for B-agonisE,s) ongoing therapy with aerosol sE.eroids
and/or masE,-ce11 sE,abilizers with infrequent, doses of B-
agonisE,s will usually suf f ice f or maint,enance. A long-
t.er:rn goal should be Eo decrease aerosol steroid doses Eo
E,he minimum amount reguired to maintain control, t,hereby
reducing t,he risk of adverse ef fecE,s (HaahEela et. dI. ,
t994) . ModeraE.e asthma resisE.ant t.o this initial
combination of drugs may require higher aerosol steroid
dosage, a short course of oral st,eroids, and/or treatment
with theophylline.
Severe asthma characterisE,icly combines nearly
continuous daytime s)rmpt,oms, freguent, night,t.ime s)rmpt,oms,
recurrenE exacerbations, marked limitations of acEivit,y,
and occasional hospitalization or emergency treatment,.
PEFR usually runs at <60? of normal baseline values and
varies >20-30? even with regular Eherapy. Treatment,
consists of regular daily doses (3-4 times per day) of
shorE, acE,ing aerosol B-agonisEs, or bronchodilation
maintenance wit.h long-act.ing salmeterol combined with
supplemental short-act.ing agenE,s for suddenly worsening
dyspnea. Daily high-dose aerosol steroids, daily masE
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ceI1 stabilizers, t,heophylline, and oral B-agonist,s,
combined with stricE avoidance of triggers are typically
required. Maint,enance t,herapy with low dose oral steroids
is ofEen necessal'y. ExacerbaE,ions are E,reaE,ed with high-
dose aerosol B-agonist,s (delivered by MDI or nebulizer)
and short, courses of higher dose oral sEeroids (40 mg per
day for 1 week, Ehen t,apering back Eo normal mainE,enance
doses by 5-10 mg per day over a second week) (National
Asthma EducaE,ion Program ExperE, Panel Report,, 1-997. ;
Kaliner, Martin, O'Byrne, & Wiedemann, ]-9921. The care of
patients wit,h severe asE,hma is best handled by a
pulmonary medicine or asthma specialist rather t,han
primary care pracEitioners as E,hese pat,ient,s are at t.he
great,est risk of disease or medicaE,ion related morbidity
and mortalit.y (National Asthma Education Program Expert
Panel ReporE,, 1991) .
TREAITIIE}flT OF EXERCISE- TNDUCED BRONCHOSPASM
EIB is generally mild and self -limiE,ed (resolving
spontaneously in 20-30 minuE,es) and only occasionally
leads t,o laEe-phase inflanunaEory responses. Pat,ient,
discomfort, and performance limitation can be sigmificant
however. Since patient,s whose exercise is limiE,ed by
breaEhlessness demonst,rate decreased venEilat,ory capacity
rat,her E,han oEher meEabolic abnormalit,ies (Mahler a
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Harver, 1988; Freeman, Nut,e, Brooks, & Williams, 1990) .
Accordingly, the main therapeut,ic focus is on maintaining
normal PFT and acEivity levels with E,reatment, which is
safe and convenient for Ehe patient. When paEients
exhibit, coughing, dyspnea, wheezing, chesE, E,ighEness, or
acE,iviE,y limitat,ion wiEh sErenuous exercise, and
associaEed declines in baseline PFTs >10?, therapy
includes prophylacE,ic short,-acting aerosol B-agonists
and/or cromolyn or nedocromil E,aken 15 minuE,es before
exercise (McFadden & Gilbert, 1994; Mahler, 7993;
Svenonius, Arborelius, Wiberg, & Ekburg, 1988).
Albut,erol has been shown Eo provide more consistent,
relief than cromolyn at. normally recormnended doses (Rohr,
Siegel, Katz, Rachelefsky, SpecE,or, & Lanier, 1987) , buE
higher doses of cromolyn can safely provide addiE,ional
relief (Katz, 1985). Preexercise prophylacE,ic sEeroids
do not influence EIB but steroid based conErol of
unstable asthma may reduce acE.iviEy-induced
exacerbations. AlE,hough use of many B-agonisEs and
khellin derivatives by ast,hmat,ic athleEes is accepEed by
sporE,s regulating organizations, several dnrgs are banned
including ephedrine, epinephrine, met,aproterenol and
isoproterenol (Voy, 1986) .
The experimenE,al leukotriene D4 receptor ant,agonist
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MK-571 has been used in aE, te5st one EIB study and found
Eo dramatically reduce sympEoms but, t,he role of Ehese
agenE,s in t,reatment, witl require further invest,igation
(Manning et, aI. , 1990) . Appropriat,e wann-up meEhods (15
minuE,es of cont,inuous exerci.A ut 60? vO, max) (McKenzie
eE aI. L994) can modify symptoms by deliberately
triggering sympEoms, inducing la one t,o E,wo hour
refract,ory period E,imed t,o ovdrlap compet,it,ion or
prolonged exercise. Physical activity in a warm, humid
environment (indoors, swinuning in an enclosed pool area,
etc.) can reduce sympt,oms (tnlailler, 1993). If exercise
musE, E,ake place outdoors ir, 
"Jra, dry conditions, using a
facemask or scarf wrapped around t,he nose and mouth can
provide at. least some addit,ional condiE,ioning of inhaled
air, reducing the heaE, and water flux which triggers
sympEoms. Some activities appear less likely to induce
EIB even under ident,ical envirbnmenE,al conditions and may
be more appropriat,e for personb with EIB resisEant Eo
I
therapy. For example, swimming provokes less EIB E.han
running, even at similar fevef! of metabolic demand (Bar-
Yishay et aI . , L982) . For ashtmat,ics, mainE,aining
fitness can improve overall puimonar), function E,hroughouE
exercise (Freeman, 
€E aI. 1990), and increase exercise
t.olerance (Haas, Pineda, Axen,,Gaudino, & Haas, 1985).
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In patienEs with an unclear hist,ory which points Eo
severe or prolonged EIB, especially wit'h a patt,ern
consistent, wit,h late phase response, monit,oring PEFR
every 5 minut,es for 30 minut,es following exercise and
again 4-L2 hours later may provide a useful gruide for
therapy (ViranE, , L992) . Syrnpt,oms poorly cont,rolled with
t,hese straE.egies can be a marker for underlying
unconLrolled asthma.
SUMMARY
Asthma is now recognized as a chronic inflanunaEory'
disease characterized by episodes of reversible airway
obsEmcE,ion and Eriggered by exposure t.o allergens,
irritant, pollutanEs, cold air, exercise, or medications.
Airway smoot,h muscle h14>erresponsiveness, submucosal
edema, and abnormal mucus production and clearance are
regulated by acEivat,ion of irmnunologic cells and sensory
nerve C-fibers which release proinflarnmatory mediaEors
such as hist,amine, PAF, leukot,riene D4 and neuropeptides
(EachykininS, substance P, et,c. ) . Irmnediat,e, early phase
bronchoconst,riction is Eypically followed by lat,e phase
inflanunaEory changes which further sensiE,ize t,he airway,
leading Eo chronic airruay reactivity.
Recently, Ereatment, has shifted away from simply
reversing bronchospasm with E,heophylline and B-agonist,s
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to an emphasis on healing airmay inflarmnaEion via
maintenance t,herapy with aerosol corE,icosteroids.
Management, is based on a rat,ing sysE,em which considers
the freguency and severit,y of exacerbat.ions. Mild,
infrequenE, asEhma is usually weII cont,rolled with
episodic aerosol B-agonists or khellin derivatives.
Persons requiring bronchodilaEor medications more t,han L-
2 times per week or who have abnormal PEFRs between
episodes should receive mainE,enance therapy wit,h aerosol
corticosteroids supplement,ed by aerosol B-agonist,s on an
as needed basis, and perhaps masE ceII stabilizers.
Patients with severe, unremitting sympt,oms and marked
expirat.ory flow obstruct,ion require oral and aerosol
steroids, aerosol B-agonisEs, a trial of cromolyn or
nedocromil and perhaps t,heophylline. Several
experiment,al therapies are reserved for t,he most unsE,able
pat,ienE,s. Nonpharmaceut,ical approaches Eo care include
allergen and irritant, avoidance, irmnunoE,herapy, use of
spacers or modified MDI E,echniques, and moniE,oring
pulmonary funct,ion with a peak flow meter can
significanEly conEribut,e E,o improvement,s in asE,hma
st,atus. St,abilizaE,ion of the disease, and normalizing
pulmonary funcE,ion and act,ivity torerance wiEh t,he 10wesE,
doses of t,he least toxic drugs are currenE goals of
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therapy.
EfB is an intrinsic variant. of asthma, probably
triggered by airvray heaE, and mucus osmolarity changes
secondary t,o acE,iviEy-related hyperpnea. IE is usually
mild and resolves spontaneously, but can limit, exercise
performance. Pre-act.ivity B-agonists or khellin
derivat,ives can prevenE, EIB. A sympt,om f ree , l-2 hour
refractory period can be induced by 6-8 minutes of
strenuous exercise, t,imed so E,haE symptoms occur and
resolve prior to a specific event or activicy.
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APPENDIX B
INFORMED CONSENT FORM
Pur?ose of the study
This st,udy will examine whet,her sE,ricE control of
asEhma following Ehe laE,est recontrnendat,ions of Lhe
National Asthma EducaEion Program and E,he Nat,ional Heart,,
Lung and Blood InstituEe improves exercise-induced
asEhma. This will be deE,ermined by following exercise
EesL and pulmonary funct,ion EesE performance, symptom
ratings and by looking for changes in the blood leveIs of
markers associated with ast,hma.
Benefits of participat,ion
Possible imprgvement in the managemenE, of asthma and
exercise-induced asthma for st,udy subject,s is t,he main
benefit of participat,ion. This would be achieved by
improving techniques for use of medicat,ed inhalers,
provision of medicaE,ions which modify the underlying
airway irritation and may have fewer side effects,
monit,oring pulmonary funct,ion and responses to medicaEion
use (an important Eechnique for t,racking the
effect,iveness of changes in t,reatmenE) and by improving
understanding of E,he disease process and t,he imporE,ance
of proper t,herapy. EliminaEion of unnecessary or
ineffective medicaEions may also reduce side effecEs. An
improved, medically supervised, comprehensive management
plan for athleEes with exercise-induced asEhma is t,he
APPENDIX B (COntttnued)
u■timate goa■of thiS Study.
What you will be asked to do
AIl subject,s will need E,o at,t,end four t,esE sessions.
The first, session will lasE approximat,ely 1 - 1 t/2 hours
and the procedures of the study will be E,horoughly
reviewed wich t,ime included for questions and answers. A
brief medical hisEory will be gat,hered and a limit,ed
physical examination (focusing on E,he heart and lungs)
will be completed. A Ereadmill exercise t,esE will be
completed withouE using any of E,he medicat,ions you
normally Eake Lo prevent, or t,reat, ast,hma sympLoms. The
angle (grade) and speed will be increased aE t,hree minuE,e
intervals unt,iI t,he maximum exercise capacity is reached.
A simple pulmonary funcE,ion Eest which involves exhaling
forcefully t,hrough a meE,er will be measured before and
after the exercise tesE. If exercise-induced
bronchospasm occurs, you may take your usual medicat.ions
at any t,ime you wish, and emergency medicat,ions and a
t,rained healt,h care provider will also be available.
Approximately one week laE,er t,he same breat,hing and
exercise EesEs will be
repeated using any medications you normally t,ake t,o
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prevenE, ast,hma symptoms. A blood specimen will be
collecled from your arm at. t.his visit. New inhalers will
be provided and Ehe ideal technique for use of inhalers
witl be EaughE,. For Ehe next, five weeks you will Eake
eiE,her an aerosol corE,icosteroid or an inacEive placebo
(2 puffs t,wice a day) in addition to any other
bronchoditating medicaEion you would normally use. You
will be asked t,o keep records of all bronchodilaeor use
during E.his period.
The t,hird tesE, session will take place approximately
five t,o six weeks afEer Ehe starE of E,he study. The
treadmill exercise Eest and pulmonary funcE,ion test,s will
be repeat,ed and anoEher blood specimen collecEed. Your
inhaler will be changed Eo t,he alt,ernate treatmenE,
(coruicosEeroid or placebo) which you have not, yeE
received and you will use t,his treatment twice daily for
five additional weeks. A final graded exercise Eest,
peak expirat,ory flow rate measuremenLs and a venipunct,ure
will be performed at, Ehis final Eesu session on week 11
of the st,udy.
You witl be required t,o call or visiE t,he Harrnond
Heatt,h Center every two weeks during t,he study Lo reporE
progress, compliance with the new Eherapy and Eo reporE,
93 Initia■s
APPEllDfx B (continued)
any problems. This may be as simple as calling in and
leaving a messagJe t,hat, all is well or, if you are
experiencing any difficulEy, a check up aE Ehe Hea1th
Center will be required.
A f inal, opt,ional visit, E,o review your individual
result,s and discuss long-term treaEment options will be
available to all parE,iciPanEs.
Risks of participation
The main pot'ential risk of the study is triggering
your preexisting ast.hma through exercise. This is an
event common t.o ast,hmaEics and iE, is unlikely t,haE, you
would experience anyt,hing more t,han Lhe usual degree of
impairment, or discomfort, that normally occurs with
physicat act,ivity. Availability of inunediat.e treatment
for acute asthma exacerbaE,ions (albuCerol sulfate
nebulizer Eherapy, oxygen t,herapy) and the presence of
experienced personnel wit,h the capacity Eo access
emergency t,ransporEat,ion should dramat,ically limiE, the
impacE, of any such event,s.
Should you experience any overall worsening of your
ast,hma or any ot,her healE,h problems during Lhe course of
the sEudy, t,he campus health cent.er is available t,o
provide care 24 hours per day, seven days per week.
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Additional risks can somet,imes occur with medication
use. Risks associat,ed with t,he use of aerosol
cort.icosEeroids include throat, irritat.ion, hoarseness, a
bad taste in the mouth, and oral candidiasis (thrush), a
minor fungal infection of the oral mucous membranes.
Bronchospasm can rarely occur with the use of any MDI buE
the majority of participant.s would come inEo E.he study
using E,his delivery sysEem as a part, of Eheir regular
treatment, regimen. Side effecE,s from these medicat.ions
resolve when t,he medications are discontinued and thrush
is easily treat,ed wit.h medicaE,ed lozenges. Learning
proper inhaler technique reduces t,he possibility of t,hese
side effecEs, and regular medical reviews and irmnediat,e
availability of medical care will further limit these
risks.
Final1y, Ehere exist a risk of personal injury (muscle
st,rains, abrasions, conEusions, eEc . ) or hearE, problems
(abnormal heart, rhythms, heart at,t,ack, etc.) during
exercise performance as well as t,he risk of bnrising,
minor pain, infecEion and thrombosis associaE,ed with
venipuncEure buE proper E,esEing and specimen collecEion
E,echniques should minimize t,hese potential problems.
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For more informat,ion: Addit,ional det,ails related to this
study can be obEained by conEacEing:
Gerard Dunphy, R.P.A.
Hanmond Healt,h CenE,er, It.haca College 274-3L77
Gary A. Sforzo, Ph.D.
DepE. of Exercise and SporE, Sciences 274-3359
Withdrawal from the study
Part,icipat,ion in this study is purely voluntary. You
are f ree to sE.op t,aking part, aE. any t.ime you choose. You
will never be reguired Eo parE,icipaEe or compleEe any of
Ehe exercises if you decide noE, Eo do so.
ConfidenEiality
A11 of the informaE,ion gat,hered during this study will
be maint,ained ac E,he Hamnond Health Cent,er. Access by
authorized medical personnel is sErict,ly regulat,ed by
stat,e and federat law. Your individual information will
never be presented E,o anyone in such a way LhaE, will
allow you t,o be associated with the st,udy - Any
presentat,ion of daEa from E,he sEudy will always be done
in a grouped formaE.
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I authorize E,he invesEigaEors E,o contacE, and discuss my
participation in t,he sEudy with my primary care
physician. I have read E,he above and undersE,and it,s
conEenEs. I agree to participaEe in Ehis study. I
certify Ehat, I am over 18 years of age. (P1ease sign and
date. )
Signature
Date
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LETTER TO ATTENDING PHYSICIAN
Harunond HealEh Cent,er
IEhaca College
Septembet L, 1995
Dear Doctor,
I am writing Eo inform you that your paEienE,
, will be volunEeering for
part,icipation in a st,udy of asthma and exercise-induced
ast,hma.
As I am sure you are aware, many people with moderat,e
ast,hma experience sympEoms caused by exercise which can
limit athletic performance. TreaEmenE, in the recent pasE
focused on t,he use of bronchodilat.ors which provide
symptomatic relief . Current,ly, great.er emphasis is
placed on managing t,he underlying inflanunaE,ory component,
of the disease wit,h aerosol cort,icosE,eroids. The purpose
of t,he proposed study is to det,ennine whet,her st,rict,
cont,rol of moderat,e to moderately severe ast,hma,
according Eo Ehe lat,est EherapeuE,ic aruidelines, will
improve exercise-induced bronchospasm and athleEic
performance as det,ermined by maximal graded exercise
98
APPENDIX C (continued)
tesEing, pert,inent measures of pulmonary function,
patienE, ratings of slmpt,oms and bronchodilator use, and
humoral markers of inf lanrnat,ion and aliergic sensit,ivity.
SubjecE,s will compleEe an informed consent, form, a
medical history and a brief cardiopulmonary physical
exam. A peak expiraEory flow rate EesE, and spirometry
will be complet,ed before exercise and a graded exercise
test to deEermine maximal oxygen consumption will be
performed according t,o the Bruce protocol; posE,-exercise
peak flow rate deEerminat,ions and spirometry will be
measured. PaEienEs will perform one baseline tesE in an
unmedicated state and a repeat, tesE one week lat.er while
following t,heir normal pre-exercise medicat,ion regimen.
A venipuncEure will also be performed for analysis of
toE,al eosinophil counE, of venous blood. One half of t,he
group will be randomly assigned Eo E,ake a placebo and Ehe
oE,her half will be assigned t,o receive an aerosol
corticosteroid (Aerobid [flunisolide] 2 puffs BID) in
addit,ion E,o t,heir usual medications; addit,ionally, ideal
inhaler use techniques will be EaughE. Subjects will be
t,aughE, symptom and medicaEion use logging and will report,
resulEs on weeks two and four of the new regimen.
Four weeks after sEarE,ing Ehe assigned t,herapy, a
repeat, of aII measures and a second venipuncture would be
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completed. Crossover of t,he treatment, and placebo groups
will be done after the second test session and Ehe
paE,ienE,s will use Ehe alE,ernaE,e inhaler for four
additional weeks when a final E,esE, session (including
graded exercise EesE, peak expiratory flow raE,e and
venipuncture) will be complet,ed.
Approximat,ely 14 subjects would be recrrriE,ed for the
study, all of Ehem having moderate to moderately severe
asthma. This degree of disease would be defined as
having daily wheezing, shortness of breath or coughing,
the paE,ienE, needing bronchodilaE,or medicat,ions more Ehan
one or two times per week and having syrnpE,oms which
disrupE normal daily acEivities. Object.ive
classificat,ion will be based on E,he posE,-exercise changes
in pulmonary funct,ion EesLing; subjects with severe
changes (<50? predicted peak expirat,ory flow rat,e posE-
exercise in an unmedicat,ed sEaEe) will be excluded from
the st,udy.
The tesE sessions will be conducE,ed by a board
cert,ified physician assist,ant, wich over t,en years of
primary care experience. Emergency medicaEions
(nebulized albut,erol sulfaEe, oxygEn, eE,c.) will be
available during all test, sessions and E,he paE,ienE, has
access to emergency healt,h care 24 hours per day, seven
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days per week aE Ehe Hanmond Healt,h Center on lt,haca
College campus. Biweekly inEerval check-ups between E,est
sessions will be required so t.haE, patient,s must regularly
reporE, progress and/or problems. The protocol has been
reviewed and approved by Ehe A11 CoIIege Review Board for
Human Subject Research and t,he sEaff physician who is
IEhaca College's Director of AE.hletic Medicine and E,eam
physician.
I have enclosed a copy of P. J. Barnes article from
E,he New England Journal of Medicine (L992) which clearly
addresses Ehe topic of inhaled corticosE,eroids in t.he
Ereatment, of moderat,e asthma. I would also be happy to
speak with you about Ehe study and E,he participaEion of
Ehis paEient. I can be reached aE Ehe Hanrnond Healt,h
Center aE, (607) 274-3L77 weekdays from 9 AIt'l to 4:30 PM.
Thank you.
Sincerely,
Gerard Dunphy, R.P.A.
■0■
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MEDICAL HISTORYFORM FOR EXERCISE―INDUCED ASTHMA STUDY
Name Student ID Number
Date
1. Approximat,ely how long have you had asEhma?
2. Please lisE. all allergies (pollens, dusE, medications,
f oods, et,c. )
3. Please list, all current medications
and oE.her prescription medicines, over
et,c. )
6. How often
shortness of
EXERCttSE?
CONTINUED ON
(asthma, allergy
the counter
medicines, etc. )
4. Have you ever been hospitalized due t'o severe asthma
or exercise-induced asEhma?
IN THE LAST TWO WEEKS...
5. HOW Often do you use your bronchodi■ator medications?
(VentO■in′ Proventi■′ a■butero■′ Brethine′ t rbuta■ine′
Number of days per week-
ToEaI doses per week-
do you have wheezing, chest t,ight,ness,
breat,h, or prolonged coughing NOT RELATED TO
Number of days per week-
NEXT PAGE ===>
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7. How ofE.en do you have wheezing, chesE Eight,ness, shorEness
of breath, or prolonged coughing CAUSED BY EXERCfSE?
Number of days per week_
8. How often do you have wheezing, chest, t,ighE,ness, shorE,ness
of breat,h, or prolonged coughing AT NIGHT?
Number of days per week_
9. How often does exercise-induced bronchospasm limit your
performance (pracE,ice or compeEition) in at,hletics?
EsEimaE,ed percenEage of t,imes t,haE, limitation is
noted_?
l-0. How severely does exercise-induced bronchospasm limit
your at,hlet,ic performance (practice or compeEit,ion) ?
t------t------l
No impact on l,imits performance Severely limitsperformance moderately performance
Place an rrxil on t,he line above the degree of esE,imat,ed
limitation
11. P1ease review iE,ems 4-9 above; overall would you say your
exercise-induced ast,hma is improved, unchanged or worse?
t-----t--t-----t----t-t---------t
Much Moderat,ely Slight,ly No Slightly Moderat,ely Much
BetE,er Bet,t,er Bet,t,er Change Worse Worse Worse
CONTINUED ON NEXT PAGE ===>
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L2. Do you have any history of heart, or cardiovascular
diseases? (high blood pressure, irregular heartbeat,
heart, valve disease, etc.)
L3. Have you recenE,ly been diagnosed or t'reated for an
injury or infect,ious disease? (coId, fIu, mononucleosis,
chickenpox, et,c. )
14. Are you currentlY using
inhaler per month?-
15. what types of exercise,
do you regularly engage in?
more than one bronchodilaEor
sports or physical act,ivities
L6. How of E,en do you exercise and approximat'eIy how long
per session? (i.e. 20 minutes three t,imes per week,
eE,c. )
L7. Has your exercise
the past, 5-8 weeks? (
season, injury, eE,c. )
L8. Do you anE,icipaEe
in the nexE 2 monEhs?
patEern changed significantlY in
due to sE,art, or finish of a sPorE
a change in your exercise PaLt,ern
r.04
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How to use your
metered-dose inhaler
r If you regularly have trouble
tireathing because of asthma or an-
other respiratory problem, your
doctor may suggest that you use a
metered-dose inhaler. This guide
will tell you more about metered-
dose inhalers and how to use yours
correctly and with confidence.
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APPENDIX E
What is a metered-dose inhaler?
A metered-dose inhaler is a small container that holds medicine under pres-
sure, much like a spray can holds paint under pressure. Each time you use
it, the inhaler releases the same small amount of medicine in the form of a
very fine mist.
Why should I use an inhaler?
The most important reason for using an inhaler is that it delivers medicine
directly to your lungs. Other types of medicine, such as tablets and synrps,
must first be absorbed through your stomach. If you follow your doctor's in-
structions carefully, the inhaler should help make your breathing easier.
How often will I need the inhaler?
Your doctor will tell you how many "puffs" of medicine you need each day
and when to take them.
Here's the right way to use it:
Because each puff delivers only a small amount of medicine, it's important
to use your inhaler correctly to get the best results. These are the firsr
steps:
l. Shake the container well.
2. Hold the container, mouthpiece end down. (lf you are using the inhaler
for the first time, or if it hasn't been used for a while, do a test spray into the
air to see if it creates a mist before using it yourself. ) Then, with the con-
tainer 2 inches away from you,r mouth, open your mouth widely and tilt
your head back slightly (Figure 1). Tilt-
ing your head back helps the medicine
reach your lungs instead of hitting
the back of your throat.
Figure 1 
- 
Hold inhaler 2 inches away lrom your
open moulh and till your head back slightly.
G UIDE
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Now, the most important steps:
3. Breathe in very slowly. At the same time, squeeze the contain-
er downward into the mouthpiece (Figure 2). It is important that
you do this just as you begin to breathe in-not before or near the
end of breathing in.
4. Continue to breathe nuery slouly; take five to ten seconds to
breathe in completely (Figure 3).
5. After you have breathed in fully, hold your breath for ten sec-
onds. ?lrrs is aery important; now the medicine is settling in your
lungs.If you cannot hold your breath for the full ten seconds, hold
it for as long as possible before you breathe out.
6. If your doctor has instructed you to take a'second or third puff, repeat
steps 1 through 5. Do this slowly. Waiting severalminutes between puffs
helps you get the best results from your medicine.
7. If your doctor tells you to rinse or gargle with water, do so after taking
your last puffof medicine.
What if I can't use the inhaler easily?
Ask your doctor about lever attachments that can make it easier to squeeze
the container downward. You can also ask about "spacers, " which attach to
the inhaler and deliver the medicine more slowly into your mouth and more
completely into your lungs.
How can I tell when the inhaler is empty?
Try this test: Float the metal container in a basin of water. If it sinks part
way, there is still medicine in it. If the container floats on its side, it is alrnost
empty and you should carry a spare.
Do I need to clean the inhaler?
Yes. You should rinse the inhaler at least once a day to help prevent clog-
grng. Rem-ove the metalcontainer and rinse the plastic case and cap with
warm water. Dry them thoroughly before you put the inhaler back togeth-
er. Be sure to replace the cap to keep out dust and other foreign objects.
What if my condition gets worse?
Callyour doctor. Also callif you feelthe need to use the inhaler more often
than prescribed. Your doctor may find that you are not using the inhaler
properly or may want to adjust the amount of medicine you are taking.
Special instructions for you:
Figure2-Squeezedown
as you breathe in slowly.
Figure 3 
- 
Take 5 to l0 seconds
to breathe in completely.
If you have questions, call me:
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Tab■e F―■
ANOVA Of Fluniso■ide and P■acebo Effects on GXT HR max
墾       ⊇二      MS      E       p
Tota1        628694.22        ■  6 8694.22  45374.88       .00
subjects       ■629.78        5     325.96     23.53       .00
Treatment         5.44        2       2.72       .20       .83
Error           ■38.56       ■0      ■3.86
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Tab■e F-2
ANOVA of F■uniso■ide and P■acebo Effects on GXT V02 maX
S旦      ⊇E      望塁     二      p
Tota■         28■ 87.29        ■   28287.29   2409.88       .00
Subjects        8■6.0■        5     ■63.20     ■3.95       .00
Treatment         7.48        2       3.74       .32       .73
Error           ■■6.97        ■0     ■■.70
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Tab■e F…3
ANOVA of F■uniSo■ide and_P■acebo_Effects on GXT RPE max
旦旦      ⊇二      塁塁      E       p
Tota1          5796.06        ■    5796.06   884■.44       .00
Subj ects          2.28        5        。46 .69。 4
Treatment         2.■■    2       ■.06    ■.6■      .25
Error             6.56       ■0    .66
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Tab■e F-4
ANOVA of F■uniso■ide and P■acebo Effects on GXT Duration
墾       ⊇E      M塁      旦  p
Tota■          2522.■6        ■ 2522.■6  ■3422.47       .00
Subjects         45.57        5       9。■■     48.50   .00
Treatment          .■■   2        .06       .3■       .74
Error             ■.88     ■0     。■9
■■0
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Table F-5
ANOVA of F■uniso■ide and Placebo Effects on GXT Ve_max
墨       ⊇E      MS      E       p
Tota■        ■85562.32        ■ ■85562.32   ■677.7■       .00
Subjects       ■■49.75        5     229。95   2.08       .■5
Treatment       550。92        2     275.46      2.49       。■3
Error          ■■06.04        ■0 ■■0.60
■■■
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Tab■e F-6
ANOVA of F■unisolide and Placebo EffeCts on GXT FVC Measurёd
Before. at 5 Minutes Postexercise and at ■5 Minutes Postexercise
墨
Total
Subj ects
Treatment
Error
lnterval
Treatment x
lnterval
546620。■7
9737.06
47.44
444.44
236.78
66.44
■  546620。■7
5    ■947.4■
2      23.72
20     22.22
2     ■■8.39
4      ■6.6■
24597.9■
22.7■
.28
2.29
。75
????????
。■5
.57
■■2
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APPENDIX F (continued)
Tab■e F-7
ANOVA of Flunisolide and Placebo Effects on GXT FEV■ Measured
Before, at 5 Minutes Postexercise and at ■5 Minutes Postexercise
墨
Tota■
Subjects
Treatment
Error
lnterval
Treatment x
lnterva■
478649.■9
■■■40.■5
.48
576.59
63■.59
28。74
■  478649。■9
5    2228.03
2        .24
20     28.83
2     3■5.80
4       7.■9
■6602.68
24.94
.00
2.94
.25
.00
.00
■.00
。■0
.9■
■■3
??
墾
??
?
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Table F-8
ANOVA of F■unisolide and P■acebo Effects on GXT PEFR Measured
Before, at 5 Minutes Postexercise and at ■5 Minutes Postexercise
Tota■
subjects
Treatment
Error
lnterva■
Treatment x
lnterva■
526683.■
733.98
25。■5
■■30.04
■395。8■
40.4■
■  526683.■3
5     ■46.60
2      ■2.57
20     56.50
2     697.9■
4      ■0.■0
932■.52
.77
.07
5.66
.■8
?????
?
.02
.95
■■4
墨 pニ墾
??
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APPENDttX F (continued)
Tab■e F-9
ANOVA of Fluniso■ide and Placebo EffeCts on GXT MMEFR Measured
Before. at 5 Minutes Postexercise and at ■5 Minutes Postexercise
pE醒璽聾
Total
Subjects
Treatment
Error
lnterva■
Treatment x
lnterval
240■33.35
■6477.43
■66.26
860.26
■08■.37
69.52
■  240■33.35
5    3295。49
2      83.■3
20     43.0■
2     540.69
4      ■7.38
5582.8■
24.24
.6■
2.06
.40
.00
.00
.56
。■8
.80
■■5
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Table F―■0
ANOVA of F■uniso■ide and P■acebo Effects on GXT FVC Preexercise
vs. Postexerc■se
pE墾璽墨
Tota■
Subjects
Treatment
Error
456.02
950.86
■40.25
736.■5
■
5
2
■0
456.02
■90。■7
70.■3
73.6■
6.■9
2.58
.95
.03
.■0
.42
■■6
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Tab■e F―■■
vs. Postexerc■se
p??咀
??
?墨
Tota■
subjects
Treatment
Error
■270.08
2079。46
26.04
■002.82
■
5
2
■0
■270.08
4■5.89
■3.02
■00.28
■2.67
4.■5
。■3
.0■
.03
.88
■■7
APPENDttX F (continued)
Tab■e F―■2
ANOVA of Fluniso■ide and P■acebo_Effects on GXT PEFR Preexercise
vs. POStexerc■se
墨       ⊇E      望旦     二      p
Tota1          207■.53        ■  207■.53     ■6.83       .00
subjects       ■806.88        5     36■.38      2.94       .07
Treatment        ■0.24        2       5.■2  04       .96
Error          ■230.7■      ■0   ■23.07
■■8
APPENDIX F (continued)
Table F―■3
ANOVA of F■unisolide and P■acebo Effects on GXT MMEFR Preexercise
vs. Postexercise
墨       ⊇里      望旦      E       p
TOta■          4098。■4        ■ 4098.■4     24.05       .00
Subjects       7802.70        5    ■560.54 9。■6  .00
Treatment        ■6.■4     2       8.07       .05       。95
Error          ■703.93       ■0  ■70.39
■■9
APPENDIX F (continued)
Table F―■4
ANOVA of F■uniSo■ide and P■acebo EffeCts on GXT Postexercise
Bronchosつasm Svmotoms at 5 and ■5 Minutes After ComD■e ion
翌       ⊇二      MS      E       p
Tota■           ■93.39        ■ ■93.39     29.46       .00
subjects         82.44        5      ■6.49 2.5■    .■0
Teatment         ■■.03     2       5.5■.84       .46
Error            65。64     ■0    6.56
■20
APPENDIX F (continued)
Tab■e F―■5
ANOVA of F■unisolide and P■acebQ_EffeCts on Tota■ E sin Dhil
Count
醒
??
?墨 p里
Total
Subjects
Treatment
Error
4370938.89
■303429。78
5682■.78
■69759,56
■ 4370938.89
5  260685。96
2   284■0。89
■0  ■6975。96
257.48
■5.36
■.67
.00
.00
.24
■2■
APPENDIX F (continued)
Tab■e F―■6
ANOVA of FluniSo■ide and P■acebo Effects on Svmoしomo■qv
lndicators
Bronchodi■ator medication use: days per week
塁塁       ⊇二       巫旦       E
Total
Subjects
Treatment
Error
■47.35
87.07
■.36
4.47
■47.35
■7.4■
.68
.45
329.47
38。94
■.52
■
5
2
■0
.00
.00
.27
Bronchodilator medication use: doses per week
墨        璽       墾
Total
Subjects
Treatment
Error
555.56
748.44
4.78
■03.22
■
5
2
■0
555.56
■49.69
2.39
■0.32
53.82
■4.50
.23
.00
.00
.80
(table continues)
■22
?
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APPENDIX F (COntinued)
Rating of symptoms provoked by exercise
墨        璽      墾 p
?
?
Total
subjects
Treatment
Error
■65.0■
43.57
9。36
■4.3■
■65.0■
8.7■
4.68
■.43
■■5.35
6.09
3.27
■
5
2
■0
.00
.0■
.08
Rating of symptoms not
墨
provoked by exercise
DF MS p??
Total
subjects
Treatment
Error
■33.39
■09。■■
■4.78
58.72
■
5
2
■0
■33.39
2■.82
7.39
5。87
22.72
3.72
■.26
.00
.04
.33
table continues)
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APPENDttX F (continued)
Exerc■se―■nduced bronchospasm frequency
旦呈       ⊇E       M呈     二        p
Tota■          954■.44        ■  954■. 4     46.7■       .00
Subjects       3625.2■     5     725.04      3.55       .06
Treatment       478.54        2     239.27      ■.■7       .36   4
Error          ■429.79        7     204.26
Exercise―nduced bronchospasm severity
SS       ⊇二     巫呈      E        p
Tota1           235。77        ■   235。77    430.04       .00
subjects         ■2.79     5       2.56      4.67       .02
Treatment          .27        2        .■4 .25  .78
Error             4。93    9        .55
(tab■e continues)
■24
APPENDIX F (cOntinued)
Rating of nocturnal asthma symptoms
阻        璽       醒 p
?
?
Total
subjects
Treatment
Error
80.22
53。78
8.69
28.8■
■
5
2
■0
80.22
■0。76
4。35
2.88
27.85
3.73
■.5■
.00
.04
.27
Rating of overa■■ asthma severity
墾         璽
?
?咀
Total
subjects
Treatment
Error
245。68
3.40
.69
5.47
245.68
.68
.35
.55
448.96
■.24
.63
■
5
2
■0
.00
.36
.55
■25
APPEDIDIX F (cont,inued)
Table F-L7
ANOVA of Flunisolide and'Placebo EffecEs on GXT VOz During EachTesr. Measured at the End of Each 3 MinuEe SEaqe
墨       ⊇旦      巫塁      旦      p
Tota1           577.23        ■    577.23    269.06       .00
Subjects        365.26        5      73.05     ■2.79   0
Treatment          .34        2        .■7  .03    .97
Error            57.■4     ■0     5。7■
Interva1       2574.66        4     643.66     42.95       .00
Treatment x       5.23        8        .65       。30 .9
1nterval
■26
APPENDIX F (continued)
Tab■e F―■8
ANOVA of F■uniso■ide and P■acebo Effects on GXT HR Durino Each
Test, Measured at the End of Each 3 Minute Stace
DF 醒墨 p
?
?
Total
subjects
Treatment
Error
lnterval
Treatment x
lnterval
205■7.20
■40■.68
35.67
603.4■
25837.63
■54.84
■   205■7.20
5     280.34
2      ■7.84
27     22.35
4   66459。■
8      ■9.36
9■8.05
2.84
.■8
47.78
.87
.00
.08
.84
.00
.56
■27
APPENDIX F (COntinued)
Tab■e F―■9
p??墾璽聾
Tota■
subjects
Treatment
Error
lnterva■
Treatment x
lnterval
5306.0■
■934.75
■4.■2
■050.24
■8459。92
383.68
5306.0■
386.95
7.06
38.90
46■4.98
47.96
■36.4■
6.■
.■■
20。70
■.23
■
5
2
27
4
8
.00
.0■
.90
.00
.32
■28
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Test, Measured at the End Of Each 3 Minute Stace
APPENDIX F (continued)
Tab■e F-20
Exercise perfoェlllance lndicators, Tota■ E sinoDhi■ COunt and
Svlnotomo■αv lndiantnrc
Variable USual Recimen
Mean (SD)
Flu isolide
Mean (SD)
Placebo
Mean (SD)
Maximum heart rate
Maximum oxygen
consumpt,ion(mI'kg-''min-')
Maximum raEing ofperceived exert,ion
Graded exercise EesE
duraEion
Maximum vent,ilat,ion(L/min)
Post.exercise s).mpEoms
aE5&15minut,es
after exercise E,esE
Tot,al eosinophil
counE
■86.5
(■■.84)
38.67
(9。44)
■7.50
(.84)
■■.74
(■.89)
94.40
(■6.6■)
4.25
(2.72)
477.33
(3■0.32)
■86.5
(■■.62)
40.■2
(6.49)
■8.33
(.52)
■■.85
(■.75)
■07.88
(■0.5■)
2.33
(3.27)
568.00
(389.39)
■87.6
(8.84)
39.93
(7.45)
■8.00
(0.89)
■■。93
(■.70)
■02.32
(8.05)
3.25
(3.40)・
433.00
(2■6.■4)
(tab■e continues)
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APPENDIX F (continued)
Variable Usua■ Reqimen
Mean (SD)
Flunisolide
Mean (SD)
Placebo
Mean (SD)
Bronchodilator
medicaEion use
days per week
doses per week
Racing of sympt,oms
provoked by
ex6rcise
not relat,ed
to exercise
EIB freguency
EfB severity
nocturnal
symptoms
overall ast,hma
severity
3.■7
(2.48)
5.83
(7.68)
3.83
(■.97)
4.00
(5.07)
32.00
(■4.40)
3.70
(0.97)
3.08
(2.62)
3.83
(0.75)
2.92
(2.49)
4.83
(4.67)
3.■7
(2.02)
2.■7
(■.03)
35.50
(26。95)
3。92
(■.02)
■.75
(■.47)
3.42
(0.80)
2.50
(2.43)
6.00
(9。47)
2.08
(■.9■)
2.00
(2.6■)
2■.00
(■8.■7)
3.63
(■.32)
■.50
(2.74)
3.83
(0.75)
■30
APPENDIX F (continued)
Table F-2■
FVC for Each Test Measured Before, at 5 Minutes Postexercise
and at ■5 Minutes Postexercise_JPercent of Predicted Va■ue)
Usual Regimen
Preexercise
5 minuEes
postexercise
15 minutes
postexercise
Aft.er flunisolide
Preexercise
5 minut,es
post,exercise
15 minut,es
postexercise
After placebo
Preexercise
5 minut,es
posEexercise
15 minutes
postexercise
Mean +/―SD
■03.50 ±■■.95
99.67 ±■4.■9
■0■.83 ±■5。■3
■02.33 ±■4.62
99.50 ±■4.28
■00.50 ±■4.25
■04.33 ±■■.25
95。83 ±23.0■
98.00 ±2■.47
■3■
APPENDIX F (continued)
Tab■e F-22
FEV■ for Each Test Measured Before, at 5 Minutes Postexercise
and at ■5 Minutes Postexercise
Mean +/―SD
Usual Regimen
Preexerc■se           98.33 ±■2. 3
5 minutes             89.83 ±■6。92
postexerc■se
■5 minutes            94.00 ±■6.78
postexerc■se
Aft,er flunisolide
Preexercise
5 minuE,es
postexercise
l-5 minuEes
postexercise
After placebo
Preexercise
5 minutes
posEexercise
15 minutes
postexercise
98.00 上■4.30
9■.50 ±■5.59
93.33 ±■5。28
99.83 ±■■.2■
90。■7 ±24.8■
92.33 ±24.08
■32
APPENDIX F (continued)
Tab■e F-23
PEFR for Each Test Measured Beforer at 5 Minutes Postexercise
and at ■5 Minutes Postexercise
Usua1 Regimen
Preexercise
5 minut,es
posEexercise
15 minut.es
posE.exercise
AfE.er flunisolide
Preexercise
5 minutes
postexercise
15 minut.es
post,exercise
Aft,er placebo
Preexercise
5 minut,es
postexercise
15 minut.es
posE,exercise
Mean +/―SD
■08.■7 ±■0.■3
95.00  ±6.39
96.00  ±8.49
■04.67 ±■2.72
95.00 ±■4.06
95。33 ±■3.28
■04.83 ±■0.03
93.■7 ±■0.30
96.67  ±6.3■
■33
APPENDttX F (continued)
Tab■e F-24
MMEFR for Each Test Measured Before, at 5 Minutes Postexercttse
and at ■5 Minutes Postexercise
Mean +/―SD
Usua■ Regimen
Preexerc■se            70.50 +■8.36
5 minutes              59.83 +24.23
postexerc■se
■5 minutes             63.67 ±20.73
postexercise
After flunisolide
Preexercise
5 minuE,es
postexercise
15 minut,es
posEexercise
After placebo
Preexercise
5 minut,es
postexercise
L5 minutes
postexercise
73.67 ±■ .94
63.50 ±2■.67
62.■7 ±■7.29
74.50 上■6.42
64.■7 ±26.9■
68。■6 ±28.73
■34
APPENDttX F (continued)
Tab■e F-25
GXT VOぅ
―
Usual Regimen
Mean + SD
Flunisolide
Mean tt SD
Placebo
Mean + SD
Stage
Stage
Stage
Stage
Stage
■
2
3
4
5
■5.50 ±2.32
2■.45 ±3.54
29.47 ±6.67
39.97 ±8.09
52.90 ± .00
■4。98 ±■.69
2■.■8 ±3.35
28.40 ±5。94
40.28 ±4.■7
50.■0 ±0.00
■5。■8 ±■.6■
20。77 ±4.09
28。■2 ±5.5■
40.44 ± .74
5■.90 ±0.00
■35
APPEIIDIX F (continued)
Table F-26
GXT HR by Stage
Usual Regimen Flunisolide Placebo
Mean + SD Mean i SD Mean + SD
SE,age L 111.50 +14 .98 1L0 . 00 +22 .6L l-10 . 67 +20 -88
srage 2 L32.00 +25 .26 L28 .t7 +28 .28 L28.83 +27 .85
sEage 3 160.33 +24.88 154.00 +30.98 L52.L7 +34.62
Stage 4 180.00 +12.81 L78.2Q +L3.24 180.00 + 9.08
St,age 5 L94.00 + 0.00 187.00 + 0.00 L87-00 + 0.00
136
APPENDIX F (continued)
Tab■e F-27
Usual Regimen
Mean + SD
Flunisolide
Mean tt SD
PJ-acebo
Mean + SD
SE,age 1
SE,age 2
Stage 3
Stage 4
St,age 5
30。■2 ± 4.55
42.77 ± 5.89
7■.87 ±■5.20
96.93 ±■7.06
■04.■0 ± 0.00
28.02 ± 3.26
4■.28 ± 6.43
65.57 +22.39
■03.74 ±■9.58
■04.30 ± 0.00
29.52 ± 2.74
42.88 ± 7.07
64.05 ±■8.28
98。■0 ±■■.53
■■■.40 ± 0.00
■37
APPENDIX G
Tab■e G,■
Raw Data for Subiect ■ ― Exercise perfoェlllance lndicators. Tota■
EosinoDhil COunt and SVInotomo■oov lndiCat r虫
Variable Usual ReOimen  FlunisolidePlacebo
Maximum heart rate
Max■mum oxygen
consumption
(ml・kg‐・・min‐1)
Maximum rating of
perce■ved exertion
Graded exerc■se test
duration (min:sec)
Maximum ventilattton
(L/min)
Postexercise symptoms
at 5 minutes after
exerc■se test
at ■5 minutes after
exerc■se test
Tota■ eosinophi■
count
■94
52.9
■87
50。■
■87
5■.9
■7
■3:40
■04.■
7
3
250
■9
■4:00
■04.3
■
■
270
■9
■3:30
■■■.4
4
3
■60
table continues)
■38
APPENDIX G (continued)
Raw Data fOr Subiect ■ (continued)
Variable Usual ReoimenFlun■solide P■acebo
Bronchodilator
medication use
days per week
doses per week
Rat.ing of symptoms
provoked
exercise
not relat,ed
to exercise
EIB frequency
EIB severit,y
nocturnal
sympEoms
overall asthma
severit,y
??
?
?
?
0
??
?
??
?
?
??
?
4.5
5.5
4
No
■.5
2.5
Answer
2
3.5
4
(tab■e continues)
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APPENDIX G (continued)
Raw Data fOr Subiect ■ (continued)
Variable Usual ReOimen    F■uniso■ide      p■acebo
FVC (L)
Preexerc■se
5 minutes
postexerc■se
FEV■ (L)
Preexerc■se
15 minutespost,exercise ]-049.
■05七
99七
■03を
■0■を
■00を
■04七
■05七
■05を
■04七
■0■七
■06七
■06七
■02七
■08七
■08を
5 minut,espostexercise 101?
15 minutespost,exercise l-08?
(table continues)
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APPENDIX G (COntinued)
Raw Data fOr Subiect ■ (cOntinued)
Variable Usual ReCimen    FlunisolideP■acebo
PEFR (L/min)
Preexerc■se
(perCentage)
5 minutes
postexerc■ se
(perCentage)
■5 minutes
postexerc■ se
(perCentage)
MEMFR (L/min)
Preexerc■se
5 m■nutes
postexerc■se
■5 m■nutes
postexercise
dFVC
dFEV■
dPEFR
dMEMFR
635
■■7を
520
95を
5■0
94を
625
■■5七
520
95=
495
9■を
550
■0■考
540
99を
570
■059.・
89
-2.9を
2七
-2を
―■2.5七
84 82
86
88
7784
88
-5。7七
-6.5を
―■9.7七
4.8七
80
-2.9七
■
=
-20.8七
-2.5七
■4■
APPENDIX G (continued)
Tab■e G-2
Raw Data for Subiect 2 - Exercise perfoェЩance lnd cators. Tota■
Eosinoohi■ Count and SvFnOtOmo■ocv lndicators
variable Usual Reqimen  Fluniso■ide      placebo
Maximum heart, rate L66
29.2
■66
33.3
■75
32.9Maximum oxygen
consumpEion(mI'kg-''min-')
Maximum rat,ing ofperceived exertion
at ■5 minutes after
exerc■se test
Tota■ eos■n phi■
count
■8 ■8
■2:30
■26.■
0
3
3■7
■8
■3:05
■09
4.5
4
3■0
Graded exercise E,est 12 230
durat,ion (min: s€c)
Maximum venEilation 94.5(L/min)
Post,exercise syrnptoms
at 5 minuE,es after
exercise tesE 3
4
235
(table continues)
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APPENDIX G (continued)
Raw Data for Subiect 2 (continued)
Variable Usual Regimen Flunisolide Placebo
Bronchodilator
medicaEion use
days per week 1
doses per week 1
Rat.ing of symptoms
provoked
exercise 1
not, related
to exercise 1
EIB frequency 2OZ
EIB severit,y 4.5
nocturnal
sympt,oms 2
. overall asthma 4
severiEy
2
■
20を
4.5
3
■
20七
4.75
?
??
?
??
(Eable conE,inues)
■43
?
??
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APPENDIX G (continued)
RaW Data fOr Subject 2 (continued)
Variable Usual Reqimen    Fluniso■ide      placebo
FVC (L)
preexerc■se 9■を
5 minutes
postexerc■se           86を
■5 minutes
postexerc■se           85を
FEV■ (L)
Preexercise
5 minuE,es
85七
post,exercise 7 6Z
15 minutespostexerciSe 782
92を
9■七
9■を
83を
82を
84七
?
????
?
???
??
??
88七
84を
82を
(table continues)
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APPENDttX G (continued)
Raw Data for Subiect 2 (continued)
Variab■e Usual ReOimen    Fluniso■ide      placebo
PEFR (L/min)
Preexercise
MEMFR (L/min)
Preexerc■se
5 minutes
postexerc■se
■5 m■nutes
postexerc■se
dFVC
dFEV■
dPEFR
dMEMFR
(percent.age) 108?
5 minuE,espost,exercise 530
(percenE.age) 96,<
15 minuEespostexercise 490
(percenE,age) 88t
600 6■0
■■0=
620
■■2を
6■0
■■0七
585
■06七
5■0
92を
530
96七
53 54
4843
5■48
47
44
-6.6七          ―■。0七          0七
―■0.6七          ―■.2七         -6.8七
―■8.3七          ―■.6七        ―■2.8七
―■8.9=          -4.Ot         ―■8.5を
■45
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APPENDIX G (continued)
Tab■e G-3         ´
Raw Data for Subiect 3 - Exercise perfoェ【llance lndicators. Tota■
Variab■e Usual Reoimen  F■unisolideP■acebo
Maximum heart, raE,e
Maximum oxygen
consumption(mI'kg-''min-')
Maximum raE,ing ofperceived exert.ion
Graded exercise testduration (min: sec)
Maximum venE,ilat,ion(t/min)
PosEexercise symPt,oms
aE 5 minutes after
exercise E.est
at t5 minutes afEer
exercise t,est,
Total eosinophil
count.
■89
47
■86
4■.3
■84
4■.4
■9
■2:00
■2■.7
0
0
296
■8
■■:00
■07.6
0
0
630
■7
■2:00
■05。4
0
0
405
(table continues)
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APPENDIX G (continued)
Raw Data for_豊iniΩ⊆L_■■ΩΩュL主ュユΩユL_
Variable Usual RecimenF■u iso■ide P■acebo
BronchodilaEor
medication use
days per week
doses per week'
Rating of sympE.oms
provoked
exercise
noE, related
to exercise
EIB frequency
EIB severiEy
noct,urnal
symptoms
overall asE,hma
severity
?
??
?
???
??
?
3.5
0.5
45を
4
2
■
75七
5
?
???
????
?
?
?
???
(table continues)
■47
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APPEIIDIX G (continued)
Raw DaLa for Subject 3 (cont.inued)
Variable Usual Regimen Flunisolide Placebo
Fvc (r)
Preexercise
5 minutespost,exercise 100?
15 minuE,espost,exercise 101?
FEV1 (L)
Preexercise
5 minut,es
872
postexercise 88?
15 minut,espost,exercise 89?
98?
?
??
??
?????????
????
9st
9s*
93?
89?
89?
88?
83?
81?
82*
(tab1e continues)
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APPENDIX G (continued)
Raw Data for Subiect 3 (conL■nu d〕
Variable Usua■ Reqimen    Flunisolide      placebo
PEFR (L/min)
Preexerc■se 600
(percentage) t02*
5 minutespostexercise 600
(percent.age) L02%
15 minutespostexercise 660
(percentage) LL2%
490
83を
495
84を
490
83を
560
95七
585
■00七
565
96七
MEMFR (L/min)
Preexercise
5 minutes
post,exercise
15 minutes
postexercise
dFVC                       3.■を      4 5七           -2.■を
dFEV■                      2.3著    -2.49.・          ―■.■七
dPEFR                     ■0を             ■七         4.5を
.     dMEMFR                     ■.9■ ―■4.3七      ―■.7七
5■
49
52
56
50
58
57
5948
■49
APPENDIX G (continued)
Table G-4
Raw Data for Subiect 4 - Exercise poerfoェlllance lndicato s. Tota■
Variable Usual Reqimen  Fluniso■ide      placёb
Maximum heart, rat,e 191
Maximum oxygen
consumpt,ion(mI'kg-''min-')
Maximum raE,ing ofperceived exerEion
Graded exercise Eest 13:15
durat,ion (min: see)
Maxi-mum venEilaEion 84.4
(L/min)
Postexercise symptoms
at 5 minutes after
exerc■se test
at ■5 minutes after
exercise test
Tota■ eosinophi■
count
■7
38.4
6.5
0
827
■9
■3:00
98.8
■90
40
0
0
720
■9■
39.8
■9
■3:00
■02.8
0
0
607
(table continues〕
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APPENDIX G (continued)
Raw Data for Subiect 4 (continued)
Variable Usua■ Reoimen    F■unisolide      Placebo
Bronchodilat,or
medicaEion use
days per week
doses per week
RaE,ing of sympEoms
provoked
exercise
not relat.ed
t,o exercise
EIB frequency
EIB severity
nocEurnal
syrnptoms
overall asE,hma
severity
?
??
?
???
3.5
6
3.5
2
50=
4
??
?
3
3
50を
4
?
?
?
???
?
?
?
???
table contihues)
■5■
2
APPENDIX G (continued)
Raw Data for Subiect 4 (cOntinued)
Variable Usual ReOimen    Flunisolide      placebo
FVC (L)
Preexercise           ■22を    ■25七         ■23を
5 minutes
postexercise          ■2■を    ■23を         ■20を
■5 minutes
postexercise          ■23を    ■24を         ■23を
FEV■ (L)
preexerc■se           ■■3を        ■■8を         ■■6そ
5 m■nutes
postexerc■se          ■■59.・           ■■7を         ■■9を
■5 minutes
postexerc■se          ■■59.・           ■■8を         ■20七
table continues)
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APPENDttX G (continued)
Raw Data for Subiect 4 (continued)
Variable Usual Reoimen    F■uniso■ide      placebo
PEFR (L/min)
preexerc■se           420            450            450
(perCentage)         94七           ■0■お         ■0■を
5 minut,espost,exercise 435
(percenEage) 98?
15 minut,espost,exercise 435
(percenE,age) 98t
MEMFR (L/min)
Preexercise 82
5 minut,espost,exercise 94
15 minut.espostexercise 82
440
99を
440
99を
88
87
430
96を
420
94=
96
83
99
9■
dFVC                      ―■七    …■.6七         -2.4を
dFEV■                      ■.8七    ―■七             3.4七
dPEFR                      3.6七           -2.2を           -6.9七
dMEMFR                    ■4.6七    9。■七          ■9。3お
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APPENDIX G (continued)
Table G-5
Raw Data for Subiect 5 - Exercise performance lndicators. Tota■
Variable Usua■ Reo■m n  F■unso■ide      P■acebo
Maximum heart. rate 180
Maximum oxygen
consumpE,ion
3■.5
(mI'kg-''min-')
Maximum rating of L7perceived exert.ion
Graded exercise tesE 10:15
duraEion (min:sec)
Maximum vent,ilation 74.8(L/min)
PosE,exercise sympE.oms
at 5 minut,es after
exercise test, 6
■88
43.2
■87
42.4
■8
■■:35
■7
■■:00
92.8
at ■5 minutes after
exerc■se test
Total eosinophi■
count
5
336
■■2.7
・     6
4
224
9
6
356
table continues)
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APPENDIX G (continued)
Raw Data for Subiect 5 (continued〕
Variab■e Usual ReqimenF■u isolidep■acebo
BronchodilaEor
medicaEion use
days per week
doses per week
Rating of symptoms
provoked
exercise
not. related
to exercise
EIB frequency
EIB severiE,y
nocturnal
symptoms
overall ast,hma
severity
?
??
?
?
?
??
??
7
■4
Answer
Answer
7 5
7
Answer
5
???
?
??
?
???
?
?
????
? No
???
table continues)
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APPEDIDIX G (continued)
Raw Data for Subject 5 (continued)
Variable Usuat Regimen Flunisolide Placebo
Fvc (L)
Preexercise
5 minut,es
post,exercise
15 minutes
post,exercise
FEV1 (L)
Preexercise
5 minuE,es
postexercise
15 minutes
post,exercise
93?
83?
8s?
88?
68?
739.
922
85?
85?
92+
81?
792
96+
53?
60t
94+
46*
s2Z
table continues)
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APPENDttX G (continued)
Raw Data for Subiect 5 (continued)
Variable 豆豊塁塁■_塁皇gユ璽Ωュ    F■unisolide      P■acebo
PEFR (L/min)
Preexerc■se           690            670            700
(perCentage)       ■22を           ■■8七         ■24キ
5 mi-nut,espost,exercise 540
15 minutespostexercise 520
MEMFR (L/min)
Preexercise 59
5 minut.espostexercise 32
L5 minutespostexercise 37
dFVC
dFEV■
dPEFR
dMEMFR
600 4■0
73を
490
87七
620
24
28
―■0。7七          -7.6=         -44七
-22.7七         ―■4.■七         -5■七
-24.6七         ―■0.4お         -4■.4を
-45。7七         -33.8t         -65.7七
(percentage) 96? 106t
(percentage) 922 110t
707■
54
47
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APPENDIX G (continued)
Table G-6
Raw Data for Subiect 6 - Exercise perfoェlllanc  lndicato s.
千 Total Eosinoohttl Count and Svmotomoloov lndicators
Variable Usual Reoimen  Fluniso■ide      placebo
Maximum heart, raE.e 199
Maximum oxygen 33
consumpt,ion(m1'kg-1'min-')
Maximum rating of L7perceived exertion
Graded exercise tesE 8:45
durat,ion (min: sec)
Maximum venEilaEion 86.9(L/min)
Postexerci se syrnpt,oms
at, 5 minuE,es afEer
exercise E,est, 3
at ■5 minutes after
exerc■se test
Tota■ eosinophil
count
3
920
202
32.8
202
3■.2
■8
9:00
97.9
■8
9:00
92.5
7
4
■247
2
0
760
table eontinues)
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APPENDIX G (continued)
Raw Data for Subiect 6 (conLinued)
Variable Usua■ Reoimen    F■unisolide      Placebo
Bronchodilat.or
Medication Use
Days Per Week
Doses Per Week
Rating of Syrnptoms
Provoked
Exercise
Not, Related
to Exercise
EIB frequency
EIB severity
nocEurnal
sympE,oms
overall ast,hma
severity
??? ??
?
??
?
4
■.54
20を
4
3
3.5
7.5
4
2
3.5
2.5
?
?
?
???
?
?
?
?
???
(tab1e eontinues)
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APPENDIX G (continued)
Raw Data for Subiect 6 (continued)
Variable Usual Reoimen    Fluniso■ide      placebo
Fvc (L)
Preexercise
5 minutes
posLexercise
15 minutes
posEexercise
FEVL (L)
Preexercise
5 minuE,es
postexercise
15 minutes
postexercise
■■2を
■09七
■■3を
■09七
9■七
■0■を
■■4を
■08七
■■09.・
■08著
83を
92を
■■29.‐
■■0七
■■0を
■06七
■0■を
■04七
(table continues)
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APPENDIX G (continued)
Raw Data fOr Subiect 6 (continued)
Variable Usual Reqimen    Flunisolide      p■acebo
PEFR (L/min)
Preexerc■se
MEMFR (L/min)
Preexercise
5 minutes
posEexercise
15 minutes
postexercise
dFVC
dFEV■
dPEFR
dMEMFR
460
(percenEage) 106?
5 minutesposEexercise 350
(percentage) 83t
15 minutespostexercise 400
(percentage) 922
435
■0■七
320
74七
340
79を
445
■02を
430
99七
440
■02を
57
9494
8■47
98
95
6075
-2.7七         -5.2■         ―■.8=
―■6.5を        -23.■七          -4.7を
-2■.7七        -26.4七          -3.4を
-39.4七        -50.5を         ―■3.8七
■6■
